Supplement to:

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for *CYP2D6* and *CYP2C19* Genotypes and Dosing of SSRIs

J. Kevin Hicks¹, Jeffrey R. Bishop², Katrin Sangkuhl³, Daniel J. Müller⁴, Yuan Ji⁵, Susan G. Leckband⁶, J. Steven Leeder⁷, Rebecca L. Graham⁸, Dana L. Chiulli⁹, Adrián LLerena¹⁰, Todd C. Skaar¹¹, Stuart A. Scott¹², Julia C. Stingl¹³, Teri E. Klein³, Kelly E. Caudle¹⁴ and Andrea Gaedigk⁷

¹ Department of Pharmacy, Cleveland Clinic, Cleveland, OH, USA; Genomic Medicine Institute, Cleveland Clinic, Cleveland, Ohio, USA; and Department of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH, USA

² University of Minnesota College of Pharmacy, Department of Experimental and Clinical Pharmacology, Minneapolis, MN

³ Department of Genetics, Stanford University, Stanford, California, USA

⁴ Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada; Department of Psychiatry, University of Toronto, Toronto, ON, Canada ⁵ Department of Laboratory Medicine and Pathology, Division of Laboratory Genetics, Mayo Clinic, Rochester, Minnesota, USA

⁶ Veterans Affairs San Diego Healthcare System, Mental Health Care Line University of California, San Diego, Skaggs School of Pharmacy and Pharmaceutical Sciences and Department of Psychiatry, San Diego, California, USA

⁷ Division of Clinical Pharmacology, Toxicology & Innovative Therapeutics, Children's Mercy Hospital, Kansas City, Missouri and Department of Pediatrics, University of Missouri-Kansas City, Kansas City, Missouri, USA

⁸ Philadelphia Veterans Affairs Medical Center, Philadelphia, PA, USA

⁹ Veterans Affairs Palo Alto Health Care System, San Jose Division, San Jose, CA, USA

¹⁰ CICAB Clinical Research Center. Extremadura University Hospital and Medical School, Badajoz, Spain

¹¹Division of Clinical Pharmacology, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA

¹²Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, 10029

¹³Federal Institute of Drugs and Medical Devices, Bonn, Germany

¹⁴Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, USA

Corresponding Author:

Andrea Gaedigk, Ph.D Children's Mercy Hospital 2401 Gillham Rd Kansas City, MO 64108 phone 816-234-3941 fax: 816-302-9943 email: agaedigk@cmh.edu Alternate email: cpic@pharmgkb.org

TABLE OF CONTENTS	
GUIDELINE UPDATES	4
LITERATURE REVIEW	4
GENES: CYP2D6 AND CYP2C19	5
Genetic Test Interpretation	5
Calculating CYP2D6 Activity Score.	5
CYP2D6 Copy Number Variants	б
Limitations of the Star (*) Nomenclature and Allele Assignments	7
CYP2C19 predicted phenotype	8
Available Genetic Test Options	9
Incidental Findings	9
Other Considerations	0
CYP2D6 Other Considerations	0
CYP2C19 Other Consideration	1
DRUGS: SSRIs	3
Background	3
Pediatric Studies	3
Other Considerations14	4
LEVELS OF EVIDENCE LINKING GENOTYPE TO PHENOTYPE	5
STRENGTH OF RECOMMENDATIONS	б
RESOURCES TO INCORPORATE PHARMACOGENETICS INTO AN ELECTRONIC HEALTH RECORD WITH CLINICAL DECISION SUPPORT	6
Supplemental Table S1. Genotypes that constitute the * alleles for <i>CYP2D6</i> and their effect on CYP2D6 protein	8
Supplemental Table S2. Association between allelic variants and CYP2D6 enzyme activity 42	2
Supplemental Table S3. Frequencies of CYP2D6 alleles (in %) in major race/ethnic groups 44	4
Supplemental Table S4. Genotypes that mainly constitute the STAR (*) alleles for <i>CYP2C19</i> and their effect on CYP2C19 protein	7
Supplemental Table S5. Association between allelic variants and CYP2C19 enzyme activity 50	C
Supplemental Table S6. Frequencies of CYP2C19 alleles (in %) in major race/ethnic groups 52	1
Supplemental Table S7. Evidence linking CYP2D6 genotype to fluvoxamine phenotype	3

Supplemental Table S8. Evidence linking CYP2D6 genotype to paroxetine phenotype	54
Supplemental Table S9. Evidence linking <i>CYP2C19</i> and <i>CYP2D</i> 6 genotype to citalopram/escitalopram phenotype	55
Supplemental Table S10. Evidence linking CYP2D6 genotype to fluoxetine phenotype	57
Supplemental Table S11. Evidence linking CYP2C19 genotype to sertraline phenotype5	58
Supplemental Figure S1. Metabolism of SSRIs, where bolded enzymes represent a major metabolic pathway	59
Supplemental Table S12. Drugs associated with gene-based dosing recommendations in this guideline	50
Supplemental Table S13. Genes that pertain to this guideline6	50
Supplemental Figure S2. <i>CYP2D6/CYP2C19</i> Pharmacogenetic Test Result: Clinical Implementation Workflow for EHR	51
Supplemental Figure S3. <i>CYP2D6/CYP2C19</i> Genotype and SSRI: Point of Care Clinical Decision Support	52
Supplemental Table S14. Example Implementation of this Guideline for CYP2D6: Pharmacogenetic Diplotype/Phenotype Summary Entries6	53
Supplemental Table S15. Example Implementation of this Guideline for CYP2C19: Pharmacogenetic Diplotype/Phenotype Summary Entries6	58
Supplemental Table S16. Example Implementation of this Guideline: Point of Care Clinical Decision Support	72
References	75

GUIDELINE UPDATES

The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for *CYP2D6* and *CYP2C19* genotypes and the dosing of SSRIs is published in full on the PharmGKB website (www.pharmgkb.org). Relevant information will be reviewed periodically and updated guidelines published online.

LITERATURE REVIEW

We searched the PubMed® database (1966 to December 2014) for the following keywords: (cytochrome P450 2D6 or CYP2D6) OR (cytochrome P450 2C19 or CYP2C19) AND (SSRI OR selective serotonin reuptake inhibitors OR fluoxetine OR paroxetine OR citalopram OR escitalopram OR sertraline OR fluvoxamine OR paroxetine) for the association between *CYP2D6* and/or *CYP2C19* genotypes and metabolism of SSRIs or SSRI-related adverse drug events or clinical outcomes. Key publications of clinical pharmacogenetic studies on SSRI pharmacokinetics and clinical outcomes are reported in **Supplemental Tables S7-S11**.

The *CYP2D6* and *CYP2C19* allele frequency tables are updates of those previously published in CPIC guidelines (1-4). Updates to the *CYP2D6* and *CYP2C19* allele frequency tables were made by searching the PubMed® database (1995 to 2014). The following criteria were used for *CYP2D6*: (CYP2D6 or 2D6 or cytochrome P4502D6) AND (genotype OR allele OR frequency OR minor allele OR variant OR ethnic OR race OR racial OR ethnicity) with filter limits set to retrieve "full-text" and "English" literature. The following criteria were used for *CYP2C19*: (CYP2C19 or 2C19 or cytochrome P4502C19) AND (genotype OR allele OR frequency OR minor allele OR variant OR ethnic OR race OR racial OR ethnicity) with filter limits set to retrieve "full-text" and "English" literature. In addition, reports were also identified from citations by others or review articles. Studies were considered for inclusion in the *CYP2D6* or *CYP2C19* frequency table if: (1) the ethnicity of the population was clearly indicated, (2) either allele frequencies or genotype frequencies were reported, (3) the method by which the genes were genotyped was indicated, (4) the sample population consisted of at least 50 individuals with a few exceptions (e.g., smaller cohorts that were part of larger studies) and (5) the study represented an original publication (no reviews or meta-analyses).

GENES: CYP2D6 AND CYP2C19

Genetic Test Interpretation

CYP2D6 and *CYP2C19* genetic variants are typically reported as haplotypes, which are defined by a specific combination of single nucleotide polymorphisms (SNPs) and/or other sequence variants including insertions and deletions that are interrogated during genotyping analysis. *CYP2D6* and *CYP2C19* haplotypes are assigned a star-allele (*) nomenclature to allow for the standardization of genetic polymorphism annotation (5). A complete list of *CYP2D6* and *CYP2C19* star-allele nomenclature along with the genetic variants that define each star-allele is available at <u>http://www.cypalleles.ki.se/cyp2d6.htm</u> and

<u>http://www.cypalleles.ki.se/cyp2c19.htm</u>, respectively. Information regarding *CYP2D6* or *CYP2C19* haplotypes (star-alleles) is also available at PharmGKB (<u>www.pharmgkb.org</u>). Knowing which SNPs or other genetic variants a particular test interrogates is important as the inclusion or exclusion of certain genetic variants in a pharmacogenetic test could affect the reported star-allele result.

Reference laboratories usually report a diplotype, which is the summary of inherited maternal and paternal star-alleles (e.g. *CYP2C19*1/*2*, where an individual inherited a **1* allele and a *2 allele). Commonly reported *CYP2D6* and *CYP2C19* star-alleles are categorized into functional groups (e.g., normal function, decreased function, or no function) based on the predicted activity of the encoded enzyme (**Supplementary Tables S2** and **S5**). The predicted phenotype (**Table 1, main manuscript**) is influenced by the expected function of each reported allele in the diplotype. CYP2D6 and CYP2C19 phenotype-predicting tools, such as pharmacogenetic translation tables, are being developed by CPIC and can be accessed at www.pharmgkb.org. Hicks *et al.* describes the development of the CYP2D6 translation table (6).

Calculating CYP2D6 Activity Score. Gaedigk *et al.* developed a scoring system to provide a uniform approach to assigning a predicted CYP2D6 phenotype (7). *CYP2D6* alleles are assigned an activity value as detailed in **Supplementary Table S2**. The activity value of each allele reported in the diplotype is added together to calculate the CYP2D6 activity score. For example, to calculate the activity score of a *CYP2D6*1/*17* diplotype, the activity value of **1* (activity value = 1) and the activity value of **17* (activity value = 0.5) are totaled to provide the CYP2D6 activity score of 1.5. Note that a value of 0.5 indicates decreased activity and not that the activity conveyed by an allele is half of that encoded by a normal function allele. For this guideline, the

CYP2D6 activity score is used to assign a predicted phenotype as follows: activity score of 0 = poor metabolizer, activity score of 0.5 = intermediate metabolizer, activity scores ranging from 1.0-2.0 = extensive metabolizer, and activity score greater than 2.0 = ultrarapid metabolizer. Therefore, a pharmacogenetic test result of *CYP2D6*1/*17* would result in a CYP2D6 activity score of 1.5 and a predicted phenotype of extensive metabolizer.

There is a lack of consensus in regards to whether patients with a CYP2D6 activity score of 1.0 should be assigned an extensive or intermediate phenotype (4). Pharmacokinetic data suggest that patients with an activity score of 1.0 have a higher CYP2D6 metabolic capacity compared to patients with an activity score of 0.5, but less CYP2D6 enzyme activity compared to patients with an activity score of 2.0 (7, 8). Herein, we classified patients with a CYP2D6 activity score of 1.0 as extensive metabolizers, which is consistent with the CPIC guidelines for codeine and the tricyclic antidepressants (7, 9).

CYP2D6 Copy Number Variants. Because *CYP2D6* is subject to copy number variation (gene duplications, multiplications, or deletions), clinical laboratories may report gene copy number if directly tested. Most patients will have a normal copy number of 2, with one allele inherited maternally and one allele inherited paternally. When two *CYP2D6* gene copies are present, the diplotype may be reported as follows: *CYP2D6*1/*1* or *CYP2D6 (*1/*1)2N*, where "2" represents copy number. A copy number of "1" indicates the presence of a *CYP2D6* gene deletion (the presence of a single gene), and a copy number of "0" indicates both *CYP2D6* genes are deleted. *CYP2D6* gene deletions are indicated by the *CYP2D6*5* allele. A gene deletion that is present on one chromosome may be reported as follows: *CYP2D6*5* allele is inferred. Typically, clinical laboratories will report a homozygous gene deletion as *CYP2D6*5/*5* or *CYP2D6* (*5/*5)0N.

A copy number greater than two indicates the presence of a *CYP2D6* gene duplication or multiplication. When a *CYP2D6* gene duplication is present, the diplotype may be reported as *CYP2D6* (*1/*2)3N, where "3" represents copy number. A clinical laboratory may not report an exact copy number, but rather indicate that additional copies of the *CYP2D6* gene are present (e.g., *CYP2D6*1/*2* duplication or *CYP2D6* (*1/*2)xN). In instances where a duplication/multiplication is present and the exact copy number is not reported, most patients will likely have a *CYP2D6* copy number of 3. However, individuals carrying as many as 13

CYP2D6 copies have been reported (10). Clinical laboratories typically do not determine which allele is duplicated, therefore when calculating CYP2D6 activity score the duplication must be considered for each allele reported in the diplotype (11). For example, a genotype result of CYP2D6 (*1/*4)3N indicates a patient has three copies of the CYP2D6 gene, with either two copies of the CYP2D6*1 allele and one copy of the CYP2D6*4 allele, or one copy of the CYP2D6*1 allele and two copies of the CYP2D6*4 allele. If the CYP2D6*1 allele carries the duplication the CYP2D6 activity score of this diplotype will be 2, whereas if the CYP2D6*4 allele carries the duplication, the activity score will be 1. Likewise, if the number of gene copies is not determined and it remains unknown which allele carries the duplication/multiplication, a CYP2D6 ($\frac{4}{9}xN$ genotype can be consistent with an IM (intermediate metabolizer) phenotype (CYP2D6*4xN/*9; activity score of 0.5) or an EM (extensive metabolizer) phenotype (CYP2D6*4/*9xN) assuming that xN does not exceed four copies in which case the activity score is 1 for xN=2, 1.5 for xN=3 and 2 for xN=4). As these examples illustrate, phenotype prediction will be considerably more accurate if testing determines which allele carries the duplication/multiplication and determines the number of gene copies present. Studies have been published describing the translation of CYP2D6 genotypes into predicted phenotypes when gene duplications or multiplications are present (2, 7, 11, 12).

Note that a duplication may not be detected by copy number assays when paired with the *CYP2D6*5* allele (gene deletion). A *CYP2D6*2x2/*5* diplotype for example has a duplication on one allele and a gene deletion on the other for a total number of two gene copies. This diplotype may be reported as *CYP2D6*2/*2*.

Limitations of the Star () Nomenclature and Allele Assignments*. The star (*) nomenclature has defined multiple subvariants for an allele (e.g. *CYP2D6*2* and **4*), but generally, these are not distinguished by current testing. This is of no consequence for *CYP2D6*4*, because all **4* subvariants share 1846G>A causing aberrant splicing and absence of functional protein. For *CYP2D6*2*, however, it is uncertain whether any of the sequence variations defining the suballeles convey a functional consequence. Also, there is no, or little, information regarding their frequencies because test laboratories do not discriminate the suballeles. In addition, there are numerous known variants and subvariants of uncertain function that have not been designated by the nomenclature committee.

It also needs to be realized that the accuracy of a genotype test depends on the number of sequence variations/allelic variants tested. If no variation is found, a *CYP2D6*1* will be the 'default' assignment. Depending on which sequence variations are found, the default assignment will be *CYP2D6*2* (or other). For example, if 2850C>T is present, but 1023C>T is not, the default assignment is *CYP2D6*2*. Also see 'CYP2D6 Other Considerations' below.

Recent findings indicate that a SNP in a distal enhancer region impacts allele activity on the transcriptional level (13, 14). It is not fully understood on which allelic variants this enhancer SNP is located. Emerging knowledge, however, suggests that a portion of *CYP2D6*2* alleles carrying the enhancer SNP convey normal activity while others lacking the enhancer SNP have reduced activity; the effect of the enhancer SNP in other haplotypes remains unknown. Presence or absence of the enhancer SNP likely also impacts the activity encoded by *CYP2D6*2xN* (duplications and multiplications). This SNP is, however, not included in current test panels. The activity score will be updated, if warranted, as new information becomes available.

CYP2C19 predicted phenotype. The predicted phenotype for a patient carrying the *CYP2C19*17* increased function allele in combination with a no function allele (e.g., *CYP2C19*2*) is less clear. Limited data suggest that *CYP2C19*17* may not compensate for the *CYP2C19*2* allele (15, 16). Herein, we classified carriers of the *CYP2C19*17* allele in combination with a no function allele as intermediate metabolizers, which is consistent with the CPIC guidelines for *CYP2C19* and clopidogrel (3).

Limited data are available to assess the predicted phenotypes for rare *CYP2C19* diplotype combinations that include *CYP2C19* alleles with decreased function and that have low frequencies in the general population (e.g., *9, *10). Therefore, for the purpose of this guideline the following assignments have been proposed: patients with two decreased function alleles OR patients with one normal/increased function allele AND one decreased function allele are categorized as "likely intermediate metabolizers" (e.g., *CYP2C19*1/*9, *9/*9, *9/*17*) and patients with one decreased function allele and one no function allele are categorized as "likely poor metabolizers" (e.g., *CYP2C19*2/*9*). For many rare alleles, no information regarding enzyme activity is currently available, and those with functional data have only been determined by in vitro studies. Consequently, the proposed "likely intermediate" and "likely poor" metabolizer assignments were developed for diplotypes that contain one allele with an established effect on enzyme activity and a second allele with limited or no available activity

data. The diplotypes in these new categories may be revised as new data become available, which will be updated on PharmGKB (<u>www.pharmgkb.org</u>) as needed.

Available Genetic Test Options

Commercially available genetic testing options change over time. Additional information about pharmacogenetic testing can be found at <u>http://www.pharmgkb.org</u> or the Genetic Testing Registry (<u>http://www.ncbi.nlm.nih.gov/gtr/</u>) (17). The American College of Medical Genetics and Genomics (ACMG) established guidelines for laboratory testing of *CYP2D6* in relation to tamoxifen therapy (18).

Clinical laboratories may analyze for different SNPs or other genetic variants, which are dependent on the genotyping platforms used and may affect the reported diplotype leading to discrepant results between methodologies. Additionally, laboratories may differ in how *CYP2D6* copy number variants are reported, which can potentially affect phenotype prediction. Therefore, it is important to not only know the alleles interrogated by each laboratory, but also which sequence variants (e.g., SNPs, insertions, or deletions) are tested and how copy number variants are reported. Clinical laboratories commonly give an interpretation of the genotype result and provide a predicted phenotype. Phenotype assignment for this guideline is defined in the main manuscript and supplementary data, but may differ from some clinical laboratory and/or deposited into patient medical records should be derived from validated genotyping platforms in clinical laboratories that implement the appropriate regulatory standards and best practices (e.g., CAP, CLIA).

Incidental Findings

A concern about genetic testing in clinical settings is that an individual's genotype may be predictive of an unrelated disease risk; however, variants in pharmacogenes have not been strongly associated with disease risk. A large candidate gene association study has identified a correlation between *CYP2C19* no function alleles (e.g., *CYP2C19*2*) and lower depressive symptoms in European twins (19). A subsequent study of transgenic mice suggested that *CYP2C19* overexpression in the brain was associated with reduced hippocampal volume and behavioral markers of anxiety (20). *CYP2D6* has been investigated in candidate gene studies of depression as well as personality traits (21-33). Although some nominal associations were

identified, *CYP2D6* genetic variants are not currently considered to be predictive of depression or personality traits. Notably, a recent mega-analysis of genome wide association studies for major depressive disorder did not identify any significant association between depression risk and *CYP2C19* or *CYP2D6* (34). Small isolated studies on cancer susceptibility have been reported for *CYP2C19* and *CYP2D6*, yet neither gene is currently considered to be significantly predictive of cancer risk (35, 36).

Other Considerations

Vortioxetine and vilazodone are newer drugs that inhibit serotonin reuptake, although both drugs also have other pharmacological properties. Vortioxetine is extensively metabolized by CYP2D6. The FDA recommends that the vortioxetine dose should be reduced by 50% in CYP2D6 poor metabolizers with a maximum recommended dose of 10 mg daily. Vilazodone is only minimally metabolized by CYP2D6 or CYP2C19.

CYP2D6 Other Considerations

There are several factors that cause potential uncertainty in CYP2D6 genotyping results and phenotype predictions as follows: 1) Because it is currently impractical to test for every variation in the CYP2D6 gene, genotyping assays may not detect rare or de novo variants resulting in patients being assigned a default genotype. Depending on the sequence variants (or alleles present) in a given patient, the default genotype may be CYP2D6*1/*1 (or wild-type) or another diplotype. If the rare or *de novo* variant adversely affects CYP2D6 enzyme function, then the patient's actual phenotype may differ from the predicted phenotype. 2) Sub-alleles of CYP2D6*4 and other star-alleles have been identified that harbor additional SNPs with limited or no added functional consequence (e.g., CYP2D6*4A, *4B, *4C, and *4D). Therefore, only analyzing for the defining CYP2D6*4 SNPs (100C>T and 1846G>A) is usually sufficient to determine a CYP2D6 phenotype. 3) There are multiple gene units involved in duplication and other major rearrangements. Additionally, rearranged gene structures involving CYP2D7-derived sequences may be misinterpreted as functional duplications (37). If the specific gene units involved in the duplication or other rearrangements are not specifically tested for, the phenotype prediction may be inaccurate and CYP2D6 activity over-estimated. 4) Alleles are typically assigned based on the most likely scenario of SNP linkage. For example, the vast majority of CYP2D6*4 alleles carry two 'key' SNPs, 100C>T and 1846G>A (as noted above). If a patient is heterozygous for these

two SNPs, a CYP2D6*1/*4 is typically assigned. However, the rare CYP2D6*4M subvariant does not carry 100C>T, which in isolation defines the *10 reduced function allele. Therefore, a *CYP2D6*4M/*10* assignment constitutes a valid, albeit unlikely, diplotype assignment. Taking the presence or absence of additional SNPs into consideration can distinguish the two possibilities. As such, to unequivocally assign CYP2D6 alleles/haplotypes, testing for multiple SNPs or full gene sequencing may be required. 5) The majority of laboratories assign the most likely diplotype and do not provide information regarding alternate diplotypes; if laboratories report alternate diplotypes, it may not be accompanied by information regarding the probability of the patient having the alternate diplotype. 6) Allele frequencies vary considerably among individuals of different ethnic backgrounds. For instance, CYP2D6*10 is common in Asian populations while CYP2D6*17 is common in people of Sub-Saharan African ancestry. These alleles, however, have a considerably lower prevalence in other ethnic groups such as Caucasians of European ancestry. Moreover, CYP2D6*14A is present in Asian populations and the SNP defining this allele (1758G>A) is typically incorporated into Asian genotyping panels (38). Thus, the alleles that should be tested for a given population may vary considerably. 7) Certain alleles carry genes in tandem arrangements. One such example is CYP2D6*36+*10 (one copy of the non-functional CYP2D6*36 and one copy of the reduced function CYP2D6*10). This tandem can be found in Asians and is typically reported as a default assignment of CYP2D6*10 due to the limitations of common genotyping assays. The complexities of CYP2D6 gene analysis, interpretation, and phenotype assignment are summarized by Hicks et al. and Gaedigk (9, 39).

CYP2C19 Other Consideration

There are several factors to consider when genotyping *CYP2C19*. Some of these factors may cause potential uncertainty in *CYP2C19* genotyping results and phenotype predictions and are listed as follows: **1**) *CYP2C19*2* is the most common no function allele. Subvariants of *CYP2C19*2* have been identified that harbor additional SNPs with limited or no added functional consequence (e.g., *CYP2C19*2A*, **2B*, **2C*, and **2D*). Therefore, only analyzing for the defining *CYP2C19*2* SNP (c.681G>A) is considered sufficient to determine a CYP2C19 gene, genotyping assays do not typically interrogate rare or novel variants. Depending on the sequence variants (or alleles present) in a given patient, the default genotype may be *CYP2C19*1/*1* (or wild-type) or another diplotype. If the rare or novel variant adversely affects CYP2C19 enzyme

function, then the patient's actual phenotype may differ from the predicted phenotype. 3) CYP2C19 allele frequencies vary considerably among individuals of different ethnic backgrounds. For example, CYP2C19*3 has a low prevalence among most ethnic groups, but has an allele frequency of approximately 15% in some Asian populations (Supplemental Table S6) (1). Thus, the alleles that should be tested for a given population may vary. For Asian populations, CYP2C19*3 should be included in CYP2C19 genotyping panels. 4) The SNP defining the no function CYP2C19*4 allele (c.1A>G; rs28399504) has been found in linkage with the SNP defining the CYP2C19*17 allele (c.-806C>T; rs12248560). This haplotype is designated CYP2C19*4B and may occur more frequently in certain ethnic groups, in particular the Ashkenazi Jewish population (1, 40, 41). CYP2C19*17 is an increased function allele, while *CYP2C19*4B* is a no function allele. Testing for *CYP2C19*4* in addition to *CYP2C19*17* may improve CYP2C19 phenotype prediction accuracy. It is noted that discrimination between CYP2C19*4A/*17 and *1/*4B requires additional testing to determine the phase of the variants (i.e., in *cis* or *trans*) in addition to genotyping for both c.-806C>T and 1A>G (42). 5) A recent study identified a novel allelic variant that carries the CYP2C19*17-defining increased activity -806C>T SNP, but also a nonsynonymous SNP, c.463G>T, that introduces a premature stop codon (p.E155X) (41). While this SNP appears to be rare, it may lead to considerable overestimation of activity in CYP2C19*17 carriers if not interrogated. 6) Certain genotyping platforms (e.g., Affymetrix DMET) analyze over 15 CYP2C19 star-alleles, some of which are rare and not well characterized. Therefore, uncertainty exists when translating a genotype result into a predicted CYP2C19 phenotype in instances where a patient is found to carry a poorly characterized allele. Polyphen-2 and Sorting Tolerant From Intolerant (SIFT) algorithms computationally predict the effect of these rare and poorly characterized alleles on CYP2C19 enzymatic function (3, 43). These data may assist in diplotype interpretation in instances where a poorly characterized allele is reported, but these methods are not a substitute for *in vitro* and *in* vivo analyses.

This guideline as well as those previously published for clopidogrel and tricyclic antidepressants (3, 44) define CYP2C19 ultrarapid metabolizers as those who carry one *CYP2C19*17* allele in combination with a normal function *CYP2C19*1* allele or those who are homozygous for *CYP2C19*17*. The decision to define ultrarapid metabolizers in this manner is largely based on pharmacokinetic data that show separation between *CYP2C19*17* carriers from *CYP2C19*1/*1* homozygotes (45, 46). Whether this definition of ultrarapid metabolizer is

appropriate for all CYP2C19 substrates requires further study and may depend on the impact of other metabolic pathways important for each drug. Though statistical separation in mean pharmacokinetic parameters between *CYP2C19*17* carriers and *CYP2C19*1* homozygotes has been observed, the range of pharmacokinetic data between these two genotypes often overlaps (47). Additionally, the magnitude of effect of the *CYP2C19*17* allele has been argued to be less than that observed in the opposite direction by *CYP2C19*2* or *3 alleles (47).

DRUGS: SSRIs

Background

Fluoxetine biotransformation is complex as this drug is metabolized extensively by CYP2D6 and CYP2C9 (**Supplemental Figure S1**) (48). Fluoxetine is a racemic drug that is composed of both R and S enantiomers. CYP2D6 is thought to be the major pathway for converting S-fluoxetine to S-norfluoxetine, while CYP2D6 and CYP2C9 extensively convert Rfluoxetine to R-norfluoxetine. R/S-fluoxetine and S-norfluoxetine have equal serotonin reuptake inhibition activity, but R-norfluoxetine is approximately 20 times less potent (49, 50). Although *CYP2D6* genetic variants may influence fluoxetine and S-norfluoxetine concentrations (**Supplemental Table S10**), total plasma concentrations of R/S-fluoxetine plus R/Snorfluoxetine may not vary significantly (49, 51-53). R/S-norfluoxetine has a long half-life and may take several weeks or months to reach steady-state. Limited studies have taken into consideration the long half-life of norfluoxetine, and S-norfluoxetine concentrations caused by *CYP2D6* genetic variants would influence therapy outcomes.

Pediatric Studies

The effect of *CYP2D6* and *CYP2C9* genotypes on steady state concentrations of fluoxetine was investigated in 83 children between 10 and 17 years of age (54). Genotype analysis was limited to *CYP2D6*3, *4, *5* and *6 alleles along with the *xN* multiplication event. Three phenotype groups (poor/intermediate, extensive and ultrarapid metabolizers) were defined based on the number of *CYP2D6* functional alleles. Dose-normalized plasma concentrations of R/S-fluoxetine, S-norfluoxetine or total active moieties (R/S-fluoxetine + S-norfluoxetine) were reported to vary 30 to 160-fold. The R/S-fluoxetine to S-norfluoxetine ratio decreased with increasing numbers of functional *CYP2D6* alleles (p<0.001), but no statistically significant

difference in total active moieties was observed across the three phenotype groups after 8 or 12 weeks of treatment. It is important to note that the study included only one poor metabolizer, which was grouped with intermediate metabolizers. The interquartile plasma concentrations for R/S-fluoxetine or S-norfluoxetine in the extensive metabolizer group overlapped the interquartile plasma concentration ranges of the poor/intermediate metabolizer group. There was no effect of *CYP2C9* genotype on steady state R/S-fluoxetine concentrations. Thus, it is reasonable to conclude from this study that steady state fluoxetine concentrations are highly variable for children 10 years of age and older, and median concentrations are comparable in patients with at least one functional *CYP2D6* allele.

For paroxetine, *CYP2D6* genotyping (> 20 allelic variants plus duplication events) was conducted as part of a dose escalation study in 27 children ranging in age from 8-11 years and 35 adolescents ranging in age from 12-17 years. Following administration of paroxetine 10 mg daily for two weeks, weight-normalized apparent oral clearance at steady state was lowest in poor metabolizer subjects (n=3 adolescents), and increased as the number of functional *CYP2D6* alleles increased. However, differences in oral clearance between the genotype groups became less apparent as the paroxetine dose increased to 20 mg per day, and no difference between genotype groups at 30 mg per day. With chronic dosing there was a progressive loss of CYP2D6 activity such that genotype-dependent dose-exposure relationships observed at low doses were lost, and apparent oral clearance values in poor metabolizers and extensive metabolizers were similar (55).

CYP2C19 genotyping was conducted in a study investigating citalopram and metabolite concentrations at steady state in 19 adolescents, two-thirds of which were >18 years of age. Dose-corrected steady state concentrations of S- and R-citalopram and *S/R* ratios for patients with *CYP2C19*1/*2* genotypes (n=3) were similar to those with *CYP2C19*1/*1* genotypes (56).

Other Considerations

The inhibition of CYP2D6 does not have an impact on those predicted to be poor metabolizers because activity cannot be further reduced (57). The clinical impact of paroxetine auto-inhibition in those who are predicted to be CYP2D6 ultrarapid, extensive or intermediate metabolizers is not fully understood. Low or undetectable paroxetine concentrations have been observed in CYP2D6 ultrarapid metabolizers (**Supplemental Table S8**) signifying that those individuals may not undergo phenoconversion (from ultrarapid to poor metabolizers) to a great

extent (57-59). Paroxetine drug exposure at steady state has also been observed to vary significantly between CYP2D6 phenotype groups (**Supplemental Table S8**). In contrast, some studies found that chronically administered paroxetine caused progressive loss of CYP2D6 activity resulting in oral clearance values that were similar among the phenotype groups (**Supplemental Table S8**). Higher doses of paroxetine (e.g., paroxetine 30 mg) were associated with greater CYP2D6 inhibition. Therefore, paroxetine-induced phenoconversion (from extensive to lower metabolism due to auto-inhibition) may be dose-dependent.

Other pharmacogenetic clinical guidelines and reviews exist for SSRIs. In 2007, the Duke Evidence-based Practice Center published a review of the literature and concluded that prospective studies of CYP450 genotyping in the treatment with SSRIs need to be performed to examine the utility of genotyping in clinical practice (60). In 2011, the Dutch Pharmacogenetics Working Group published pharmacogenetics-based therapeutic recommendations including recommendations for paroxetine, citalopram/escitalopram, and sertraline (61). The enclosed CPIC recommendations also reflect new literature since 2011 (through December 2014).

LEVELS OF EVIDENCE LINKING GENOTYPE TO PHENOTYPE

The evidence summarized in **Supplemental Tables S7-S11** is graded (62) on a scale of high, moderate, and weak, based upon the level of evidence:

High: Evidence includes consistent results from well-designed, well-conducted studies. **Moderate:** Evidence is sufficient to determine effects, but the strength of the evidence is limited by the number, quality, or consistency of the individual studies, generalizability to routine practice, or indirect nature of the evidence.

Weak: Evidence is insufficient to assess the effects on health outcomes because of limited number or power of studies, important flaws in their design or conduct, gaps in the chain of evidence, or lack of information.

Every effort was made to present evidence from high-quality studies, which provided the framework for the strength of therapeutic recommendations (**Main manuscript Table 2**).

STRENGTH OF RECOMMENDATIONS

CPIC's therapeutic recommendations are based on weighting the evidence from a combination of preclinical functional and clinical data, as well as on some existing disease-specific consensus guidelines. Some of the factors that are taken into account in evaluating the evidence supporting therapeutic recommendations include: in vivo pharmacokinetic and pharmacodynamic data, in vitro enzyme activity of tissues expressing wild-type or variant-containing CYP2D6 or CYP2C19, in vitro CYP2D6 or CYP2C19 enzyme activity from tissues isolated from individuals of known *CYP2D6* or *CYP2C19* genotypes, and in vivo pre-clinical and clinical pharmacokinetic and pharmacodynamic studies. The gene-based dosing recommendations in this guideline takes into consideration the affects *CYP2D6* or *CYP2C19* genetic variants may have on both clinical outcomes and SSRIs. Because the pharmacokinetic properties of SSRIs do not differ between healthy volunteers and patients, we evaluated pharmacokinetic data acquired from studies performed on healthy subjects and patients to assist us in determining if *CYP2D6* or *CYP2C19* genetic variants affect SSRIs.

Overall, the therapeutic recommendations are simplified to allow rapid interpretation by clinicians. CPIC uses a slight modification of a transparent and simple system for just three categories for recommendations adopted from the rating scale for evidence-based recommendations on the use of retroviral agents (63): 'strong', where "the evidence is high quality and the desirable effects clearly outweigh the undesirable effects"; 'moderate', in which "there is a close or uncertain balance" as to whether the evidence is high quality and the desirable clearly outweigh the undesirable effects; and 'optional', in which the desirable effects are closely balanced with undesirable effects and there is room for differences in opinion as to the need for the recommended course of action.

RESOURCES TO INCORPORATE PHARMACOGENETICS INTO AN ELECTRONIC HEALTH RECORD WITH CLINICAL DECISION SUPPORT

Clinical decision support (CDS) tools integrated within electronic health records (EHRs) can help guide clinical pharmacogenetics at the point of care (64-68). Supplementary material (**Supplemental Tables S12-S16** and **Figures S2** and **S3**) provides resources to support the adoption of CPIC guidelines within an EHR (69). Based on the capabilities of various EHRs and local preferences, we recognize that approaches may vary across organizations. Our intent is to synthesize foundational knowledge that provides a common starting point for incorporating *CYP2D6* and/or *CYP2C19* genotype results in an EHR to guide SSRI dosing.

Effectively incorporating pharmacogenetic information into an EHR to optimize drug therapy should have some key attributes. Pharmacogenetic results, an interpreted phenotype, and a concise interpretation or summary of the result must be documented in the EHR (6). Because clinicians must be able to easily find the information, the interpreted phenotype may be documented as a problem list entry or in a patient summary section; these phenotypes are best stored in the EHR at the "person level" rather than at the date-centric "encounter level". Additionally, results should be entered as standardized and discrete terms to facilitate using them to provide point-of-care CDS (70, 71). Because pharmacogenetic results have lifetime implications and clinical significance, results should be placed into a section of the EHR that is accessible independent of the test result date to allow clinicians to quickly find the result at any time after it is initially placed in the EHR. Point-of-care CDS should be designed to effectively notify clinicians of prescribing implications at any time after the test result is entered into the EHR. Guidance to achieve these objectives is provided in diagrams that illustrate how CYP2D6 and/or CYP2C19 pharmacogenetic test results could be entered into an EHR (Supplemental Figure S2) and be used for point-of-care CDS (Supplemental Figure S3). Supplemental Tables S12 and S13 provide a reference to widely used nomenclature systems for the drugs and genes, respectively, relevant to this CPIC guideline.

To incorporate a phenotype in the EHR in a standardized manner, genotype test results provided by the laboratory must be consistently translated into an interpreted phenotype (**Table 1, main manuscript**). **Supplemental Tables S14** and **S15** further translate results into a coded diplotype/phenotype summary, priority result notification, and sample interpretative result text. Finally, sample point-of-care alert text that corresponds to the workflow described in **Supplemental Figure S3** is provided in **Supplemental Table S16**.

SUPPLEMENTAL TABLE S1. GENOTYPES THAT CONSTITUTE THE * ALLELES FOR *CYP2D6* AND THEIR EFFECT ON CYP2D6 PROTEIN

Allele ^a	Major Nucleotide Variation ^b	dbSNP Number ^c	Effect on CYP2D6 Protein
*1A ^d	-	-	-
*1B	3828G>A	rs28371732	-
*1C	1978C>T	rs150163869	-
*1D	2575C>A	[rs28371718] ^j	-
*1E	1869T>C	rs111606937	-
*1xN	Gene duplication or multiplication		
	-1584C>G	rs1080985	-
	-1235A>G	rs28735595	-
	-740C>T	rs28624811	-
*21e	-678G>A	rs28633410	-
*2A	<i>CYP2D7</i> gene conversion in intron 1	-	-
	1661G>C	rs1058164	-
	2850C>T	rs16947	R296C
	$4180G>C^{f}$	rs1135840	S486T
	1039C>T	rs1081003	-
* a De.g	1661G>C	rs1058164	-
2B/8	2850C>T	rs16947	R296C
	$4180G>C^{f}$	rs1135840	S486T
	1661G>C	rs1058164	-
*200	2470T>C	-	-
*2C	2850C>T	rs16947	R296C
	$4180G>C^{f}$	rs1135840	S486T
*aDe	2850C>T	rs16947	R296C
*2D	$4180G>C^{f}$	rs1135840	S486T
	997C>G	rs28371705	-
*2 De	1661G>C	rs1058164	-
*2E	2850C>T	rs16947	R296C
	$4180\text{G}>\text{C}^{\text{f}}$	rs1135840	S486T
	1661G>C	rs1058164	-
* 2 Te	1724C>T	rs74962936	-
*2F	2850C>T	rs16947	R296C
	$4180G>C^{f}$	rs1135840	S486T
	1661G>C	rs1058164	-
	2470T>C	-	-
$*2G^{e}$	2575C>A	rs28371718 ^j	-
	2850C>T	rs16947	R296C
	4180G>C ^f	rs1135840	S486T

Allele ^a	Major Nucleotide Variation ^b	dbSNP Number ^c	Effect on CYP2D6 Protein
	1661G>C	rs1058164	-
*arre	2480C>T	rs267608298	-
*2 H	2850C>T	rs16947	R296C
	4180G>C ^f	rs1135840	S486T
	1661G>C	rs1058164	-
*2128	2850C>T	rs16947	R296C
*2A	4115C>T	rs150445731	-
	$4180 \text{G} > \text{C}^{\text{f}}$	rs1135840	S486T
	-1298G>A	rs59099247	-
	-1235A>G	rs28735595	-
	-740C>T	rs28624811	-
	310G>T	rs28371699	-
	746C>G	rs28371701	-
	843T>G	-	-
*ore	1513C>T	rs67497403	-
*2L	1661G>C	rs1058164	-
	1757C>T	rs199849357	-
	2850C>T	rs16947	R296C
	3384A>C	rs1985842	-
	3584G>A	rs28371730	-
	3790C>T	rs116917064	-
	4180G>C ^f	rs1135840	S486T
	Variable number of A's in the region -	-	-
	1258 to -1237		
	-1235A>G	rs28735595	-
	-750749delGA>del	-	-
	-740C>T	rs28624811	-
	-678G>A	rs28633410	-
	<i>CYP2D7</i> gene conversion in intron 1	-	-
	310G>T	rs28371699	-
*2M ^e	746C>G	rs28371701	-
	843T>G	-	-
	1661G>C	rs1058164	-
	2850C>T	rs16947	R296C
	3384A>C	rs1985842	-
	3584G>A	rs28371730	-
	3790C>T	rs116917064	-
	$4180G > C^{f}$	rs1135840	S486T
	4481G>A	rs116390392	-
*2xN	Gene duplication or multiplication		
*3A	2549A>del	rs35742686	Frameshift
*2D	1749A>G	rs1135824	N166D
JD	2549A>del	rs35742686	Frameshift

Allele ^a	Major Nucleotide Variation ^b	dbSNP Number ^c	Effect on CYP2D6
		10.17070	Protein
	100C>T	rs1065852	P34S
	974C>A	rs28371703	L91M
	984A>G	rs28371704	H94R
Allele ^a *4A *4B *4C	997C>G	rs28371705	-
	1661G>C	rs1058164	-
	1846G>A	rs3892097	Splicing defect
	4180G>C ¹	rs1135840	[S486T]
	100C>T	rs1065852	P34S
*4B	974C>A	rs28371703	L91M
	984A>G	rs28371704	H94R
-10	997C>G	rs28371705	-
	1846G>A	rs3892097	Splicing defect
	4180G>C ¹	rs1135840	[S486T]
	100C>T	rs1065852	P34S
	1661G>C	rs1058164	-
*4C	1846G>A	rs3892097	Splicing defect
	3887T>C	[rs72549345] ¹	[L421P]
	$4180G > C^{t}$	rs1135840	[S486T]
	100C>T	rs1065852	P34S
	1039C>T	rs1081003	-
*4D	1661G>C	rs1058164	-
	1846G>A	rs3892097	Splicing defect
	4180G>C ^t	rs1135840	[S486T]
	100C>T	rs1065852	P34S
*15	1661G>C	rs1058164	-
*4A *4B *4C *4D *4E *4F *4G	1846G>A	rs3892097	Splicing defect
	$4180G > C^{t}$	rs1135840	[S486T]
*4D *4E *4F	100C>T	rs1065852	P34S
	974C>A	rs28371703	L91M
	984A>G	rs28371704	H94R
*15	997C>G	rs28371705	-
·41	1661G>C	rs1058164	-
	1846G>A	rs3892097	Splicing defect
	1858C>T	rs370249680	[R173C]
	$4180\text{G}>\text{C}^{\text{f}}$	rs1135840	[S486T]
	100C>T	rs1065852	P34S
	974C>A	rs28371703	L91M
	984A>G	rs28371704	H94R
* 10	997C>G	rs28371705	-
*40	1661G>C	rs1058164	-
	1846G>A	rs3892097	Splicing defect
	2938C>T	rs140513104	[P325L]
	4180G>C ^f	rs1135840	[S486T]

	Major Nucleatide Variation ^b	dhCND Numhar ^c	Effect on CYP2D6
Allele	Major Nucleonde Variation	ubsini mumber	Protein
	100C>T	rs1065852	P34S
	974C>A	rs28371703	L91M
	984A>G	rs28371704	H94R
*/11	997C>G	rs28371705	-
*411	1661G>C	rs1058164	-
Allele ^a *4H *4J *4K *4K *4K *4K	1846G>A	rs3892097	Splicing defect
	3877G>C	-	[E418Q]
	$4180G > C^{f}$	rs1135840	[S486T]
	100C>T	rs1065852	P34S
	974C>A	rs28371703	L91M
* <i>1</i> T	984A>G	rs28371704	H94R
*4J	997C>G	rs28371705	-
	1661G>C	rs1058164	-
	1846G>A	rs3892097	Splicing defect
	100C>T	rs1065852	P34S
	1661G>C	rs1058164	-
*4K	1846G>A	rs3892097	Splicing defect
	2850C>T	rs16947	[R296C]
	$4180G > C^{f}$	rs1135840	[S486T]
	100C>T	rs1065852	P34S
*4H *4J *4K *4L *4M	997C>G	rs28371705	-
	1661G>C	rs1058164	-
	1846G>A	rs3892097	Splicing defect
	$4180G > C^{f}$	rs1135840	[S486T]
	-1235A>G	rs28735595	-
	746C>G	rs28371701	-
	843T>G	-	-
	974C>A	rs28371703	L91M
	984A>G	rs28371704	H94R
* 414	997C>G	rs28371705	-
**4111	1661G>C	rs1058164	-
	1846G>A	rs3892097	Splicing defect
	2097A>G	[rs58440431] ^j	-
	3384A>C	rs1985842	-
	3582A>G	rs2004511	-
	4401C>T	rs28371738	-

Allele ^a	Major Nucleotide Variation ^b	dbSNP Number ^c	Effect on CYP2D6 Protein
	-1426C>T	rs28588594	-
	-1235A>G	rs28735595	-
	-1000G>A	rs1080989	-
	100C>T	rs1065852	P34S
	310G>T	rs28371699	-
	746C>G	rs28371701	-
	843T>G	-	-
	974C>A	rs28371703	L91M
* 171	984A>G	rs28371704	H94R
*4/N	997C>G	rs28371705	-
	1661G>C	rs1058164	-
	1846G>A	rs3892097	Splicing defect
	2097A>G	[rs58440431] ^j	-
	3384A>C	rs1985842	-
	3582A>G	rs2004511	-
	gene conversion to CYP2D7 in exon 9	-	-
	$4180G>C^{f}$	rs1135840	[S486T]
	4401C>T	rs28371738	-
	-1426C>T	rs28588594	-
	-1235A>G	rs28735595	-
	-1000G>A	rs1080989	-
	100C>T	rs1065852	P34S
	310G>T	rs28371699	-
	746C>G	rs28371701	-
	843T>G	-	-
	974C>A	rs28371703	L91M
	984A>G	rs28371704	H94R
*4P	997C>G	rs28371705	-
	1661G>C	rs1058164	-
	1846G>A	rs3892097	Splicing defect
	2097A>G	[rs58440431] ¹	-
	2576C>T	-	[P268S]
	3384A>C	rs1985842	-
	3435C>A	rs28371729	-
	3582A>G	rs2004511	-
	4180G>C ¹	rs1135840	[S486T]
	4401C>T	rs28371738	-
*4xN	Gene duplication or multiplication		
*5	Gene deletion	N/A	Gene deletion
*6A	1707T>del	rs5030655	Frameshift
<u> ህ / ከ</u>	1707T>del	rs5030655	Frameshift
т 0 В	1976G>A	rs139779104	[G212E]

Allele ^a	Major Nucleotide Variation ^b	dbSNP Number ^c	Effect on CYP2D6 Protein
	1707T>del	rs5030655	Frameshift
*6C	1976G>A	rs139779104	[G212E]
	4180G>C ^f	rs1135840	[S486T]
*6D	1707T>del	rs5030655	Frameshift
012	3288G>A	rs150552908	[G373S]
*6xN	Gene duplication or multiplication ^k		
*7	2935A>C	rs5030867	H324P
	1661G>C	rs1058164	-
*0	1758G>T	-	G169X
*ð	2850C>T	rs16947	[R296C]
	4180G>C ^f	rs1135840	[S486T]
*9	2615delAAG	rs5030656	K281 deletion
*9xN	Gene duplication or multiplication		
	100C>T	rs1065852	P34S
*10A	1661G>C	rs1058164	-
	$4180G>C^{f}$	rs1135840	S486T
	-1426C>T	rs28588594	-
	Variable number of A's in the region -	-	-
	1258 to -1237		
	-1235A>G	rs28735595	-
*10B	-1000G>A	rs1080989	-
	100C>T	rs1065852	P34S
	1039C>T	rs1081003	-
	1661G>C	rs1058164	-
	4180G>C ¹	rs1135840	S486T
	100C>T	rs1065852	P34S
	1039C>T	rs1081003	-
*10D	1661G>C	rs1058164	-
	4180G>C ⁴	rs1135840	S486T
	<i>CYP2D7</i> -like 3'-flanking region	-	-
*10xN	Gene duplication or multiplication		
	883G>C	rs201377835	Splicing defect
*11	1661G>C	rs1058164	-
	2850C>T	rs16947	[R296C]
	4180G>C ⁴	rs1135840	[S486T]
	124G>A	rs5030862	G42R
*12	1661G>C	rs1058164	-
	2850C>T	rs16947	R296C
	4180G>C*	rs1135840	S486T

Allele ^a	Major Nucleotide Variation ^b	dbSNP Number ^c	Effect on CYP2D6 Protein
	CVD2D6*12 allalas share a CVD2D7/2D6		Frotein
*13	hybrid gene structure, with <i>CYP2D7</i> sequence in exon 1 leading to an insertion (137_138insT) and frameshift of the open reading frame.	-	Frameshift
*14A	100C>T 1758G>A 2850C>T	rs1065852 rs5030865 rs16947	P34S G169R R296C
*14B	4180G>C ⁴ intron 1 conversion with <i>CYP2D7</i> (214- 245) 1661G>C 1758G>A 2850C>T 4180C C ⁶	rs1135840 - rs1058164 rs5030865 rs16947	S486T - G169R R296C
	41800>C	181133840	54801
*15	137_138insT	-	Frameshift
*16	See <i>CYP2D6*13</i>		
*17	1023C>T 1661G>C 2850C>T 4180G>C ^f	rs28371706 rs1058164 rs16947 rs1135840	T107I - R296C S486T
*17xN	Gene duplication or multiplication		
*18	4125_4133dupGTGCCCACT	-	468_470dupVPT
*19	1661G>C 2539_2542AACT>del 2850C>T 4180G>C ^f	rs1058164 [rs72549353] ⁱ rs16947 rs1135840	- Frameshift R296C S486T
*20	1661G>C 1973_1974insG 1978C>T 1979T>C 2850C>T 4180G>C ^f	rs1058164 rs72549354 rs150163869 rs199535154 rs16947 rs1135840	- Frameshift [L213P] [R296C] [S486T]

Allele ^a	Major Nucleotide Variation ^b	dbSNP Number ^c	Effect on CYP2D6 Protein
	-1584C>G	rs1080985	-
	-1426C>T	rs28588594	-
	Variable number of A's in the region -	-	-
	1258 to -1237		
	-1235A>G	rs28735595	-
	-740C>T	rs28624811	-
	-678G>A	rs28633410	-
	-629A>G	-	-
*21A	partial intron 1 conversion with CYP2D7	-	-
	(214-227)		
	310G>T	rs28371699	-
	601delC	-	-
	1661G>C	rs1058164	-
	2573_2574insC	rs267608296	Frameshift
	2850C>T	rs16947	[R296C]
	3584G>A	rs28371730	-
	4180G>C ^f	rs1135840	[S486T]
	-1584C>G	rs1080985	-
	-1235A>G	rs28735595	-
	-740C>T	rs28624811	-
	-678G>A	rs28633410	-
*21R	intron 1 conversion with CYP2D7 (214-	-	-
210	245)		
	1661G>C	rs1058164	-
	2573_2574insC	rs267608296	Frameshift
	2850C>T	rs16947	[R296C]
	4180G>C ¹	rs1135840	[S486T]
*22	82C>T	rs138100349	R28C
*23	957C>T	rs267608310	A85V
*24	2853A>C	-	I297L
*25	3198C>G	rs267608295	R343G
*26	3277T>C	-	I369T
*27	3853G>A	[rs61737947] ⁱ	E410K
	19G>A	rs72549358	V7M
	1661G>C	rs1058164	-
*28	1704C>G	rs78482768	Q151E
	2850C>T	rs16947	R296C
	4180G>C ^f	rs1135840	S486T

Allele ^a	Major Nucleotide Variation ^b	dbSNP Number ^c	Effect on CYP2D6 Protein
	1659G>A; 1661G>C	rs61736512*	V136I
		(*for V136M;	
		combined with	
*20		1661G>C to	
*29		V136I)	
	2850C>T	rs16947	R296C
	3183G>A	rs59421388	V338M
	4180G>C ^f	rs1135840	S486T
*29xN	Gene duplication or multiplication		
	1661G>C	rs1058164	-
*20	1863_1864insTTTCGCCCC	-	174_175insFRP
-30	2850C>T	rs16947	R296C
	$4180G>C^{t}$	rs1135840	S486T
	-1770G>A	rs1080983	-
	-1584C>G	rs1080985	-
	-1235A>G	rs28735595	-
	-740C>T	rs28624811	-
	-678G>A	rs28633410	-
	<i>CYP2D7</i> gene conversion in intron 1	-	-
	310G>T	rs28371699	-
	746C>G	rs28371701	-
*31	843T>G	-	-
	1661G>C	rs1058164	-
	2850C>T	rs16947	R296C
	3384A>C	rs1985842	-
	3584G>A	rs28371730	-
	3790C>T	rs116917064	-
	4042G>A	rs267608319	R440H
	4180G>C ²	rs1135840	S4861
	4481G>A	rs116390392	-
	1661G>C	rs1058164	-
*32	2850C>1	rs16947	R296C
	3853G>A	[rs61/3/94/] ²	E410K
	4180G>C	rs1135840	54861
*33	2483G>T	rs28371717	A237S
*34	2850C>T	rs16947	R296C
	-1584C>G	rs1080985	-
	31G>A	rs769258	V11M
*35A	1661G>C	rs1058164	-
	2850C>T	rs16947	R296C
	$4180G>C^{f}$	rs1135840	S486T

Allele ^a	Major Nucleotide Variation ^b	dbSNP Number ^c	Effect on CYP2D6 Protein
	-1584C>G	rs1080985	-
	<i>CYP2D7</i> conversion upstream of exon 1	-	-
	(-225 to -431)		
*35B	31G>A	rs769258	V11M
	1661G>C	rs1058164	-
	2850C>T	rs16947	R296C
	4180G>C ^f	rs1135840	S486T
*35xN	Gene duplication or multiplication		
	-1426C>T	rs28588594	-
	-1235A>G	rs28735595	-
	-1000G>A	rs1080989	-
	100C>T	rs1065852	P34S
	310G>T	rs28371699	-
	843T>G	-	-
	1039C>T	rs1081003	-
	1661G>C	rs1058164	-
*36	2097A>G	[rs58440431] ^j	-
	3384A>C	rs1985842	-
	3582A>G	rs2004511	-
	gene conversion to CYP2D7 in exon 9	-	P469A
		-	T470A
		-	H478S
		-	G479R
		-	F481V
		-	A482S
	4180G>C ^f	rs1135840	[S486T]
*36x2	Duplication or tandem		
	100C>T	rs1065852	P34S
	1039C>T	rs1081003	-
*37	1661G>C	rs1058164	-
	1943G>A	[rs72549355] ⁱ	R201H
	4180G>C ^f	rs1135840	S486T
*38	2587_2590GACT>del	[rs72549351] ⁱ	Frameshift
*20	1661G>C	rs1058164	-
*39	4180G>C ^f	rs1135840	S486T
	1023C>T	rs28371706	T107I
	1661G>C	rs1058164	-
*40	1863_1864insTTTCGCCCCx2	-	174_175insFRPx2
	2850C>T	rs16947	[R296C]
	$4180G>C^{f}$	rs1135840	[S486T]

Allele ^a	Major Nucleotide Variation ^b	dbSNP Number ^c	Effect on CYP2D6 Protein
	-1235A>G	rs28735595	-
	-740C>T	rs28624811	-
	-678G>A	rs28633410	-
* 11	CYP2D7 gene conversion in intron 1	-	-
*41	1661G>C	rs1058164	-
	2850C>T	rs16947	R296C
	2988G>A	rs28371725	Splicing
	4180G>C ^f	rs1135840	S486T
*41xN	Gene duplication or multiplication ^k		
	1661G>C	rs1058164	-
* 10	2850C>T	rs16947	R296C
*42	3259_3260insGT	[rs72549346] ⁱ	Frameshift
	4180G>C ^f	rs1135840	[S486T]
*43	77G>A	rs28371696	R26H
*43xN	Gene duplication or multiplication ^k		
* 1 1	82C>T	rs138100349	-
*44	2950G>C	rs72549349	Splicing defect
	-16011600GA>TT	rs267608286	-
	Variable number of A's in the region -	-	-
	1258 to -1237		
	-10941093insA	-	-
	-1011T>C	rs59360719	-
	310G>T	rs28371699	-
	746C>G	rs28371701	-
	843T>G	-	-
	1661G>C	rs1058164	-
*45A	1716G>A	rs28371710	E155K
	2129A>C	rs267608290	-
	2575C>A	[rs28371718] ^j	-
	2661G>A	rs76015180	-
	2850C>T	rs16947	R296C
	3254T>C	[rs28371726] ^j	-
	3384A>C	rs1985842	-
	3584G>A	rs28371730	-
	3790C>T	rs116917064	-
	$4180G>C^{f}$	rs1135840	S486T

Allele ^a	Major Nucleotide Variation ^b	dbSNP Number ^c	Effect on CYP2D6 Protein
	-1543G>A	rs76210340	-
	-1298G>A	rs59099247	-
	-1235A>G	rs28735595	-
	-10941093insA	-	-
	-740C>T	rs28624811	-
	-695692delTGTG	-	-
	310G>T	rs28371699	-
	746C>G	rs28371701	-
	843T>G	-	-
*45B	1661G>C	rs1058164	-
	1716G>A	rs28371710	E155K
	2575C>A	[rs28371718] ^j	-
	2661G>A	rs76015180	-
	2850C>T	rs16947	R296C
	3254T>C	[rs28371726] ^j	-
	3384A>C	rs1985842	-
	3584G>A	rs28371730	-
	3790C>T	rs116917064	-
	$4180 \text{G} > \text{C}^{\text{f}}$	rs1135840	S486T
*45xN	Gene duplication or multiplication ^k		
	-1543G>A	rs76210340	-
	-1298G>A	rs59099247	-
	-1235A>G	rs28735595	-
	-740C>T	rs28624811	-
	77G>A	rs28371696	R26H
	310G>T	rs28371699	-
	746C>G	rs28371701	-
	843T>G	-	-
	1661G>C	rs1058164	-
* 16	1716G>A	rs28371710	E155K
*40	2575C>A	rs28371718j	-
	2661G>A	rs76015180	-
	2850C>T	rs16947	R296C
	3030G>G/A	rs267608291	-
	3254T>C	[rs28371726] ^j	-
	3384A>C	rs1985842	-
	3491G>A	rs267608292	-
	3584G>A	rs28371730	-
	3790C>T	rs116917064	-
	4180G>C ^f	rs1135840	S486T

Allele ^a	Major Nucleotide Variation ^b	dbSNP Number ^c	Effect on CYP2D6 Protein
	-1426C>T	rs28588594	_
	-1235A>G	rs28735595	-
	-1000G>A	rs1080989	-
sie 477	73C>T	rs267608313	R25W
*47	100C>T	rs1065852	P34S
	1039C>T	rs1081003	-
	1661G>C	rs1058164	-
	4180G>C ^f	rs1135840	S486T
*48	972C>T	rs267608309	A90V
	-1426C>T	rs28588594	-
	-1235A>G	rs28735595	-
	-1000G>A	rs1080989	-
* 10	100C>T	rs1065852	P34S
*49	1039C>T	rs1081003	-
	1611T>A	rs1135822	F120I
	1661G>C	rs1058164	-
	$4180G > C^{f}$	rs1135840	S486T
*50	1720A>C	rs267608302	E156A
	-1584C>G	rs1080985	-
	-1235A>G	rs28735595	-
	-740C>T	rs28624811	-
	-678G>A	rs28633410	-
*51	CYP2D7 gene conversion in intron 1	-	-
	1661G>C	rs1058164	-
	2850C>T	rs16947	R296C
	3172A>C	[rs72549348] ⁱ	E334A
	$4180G > C^{f}$	rs1135840	S486T
	-1426C>T	rs28588594	-
	-1235A>G	rs28735595	-
	-1000G>A	rs1080989	-
	100C>T	rs1065852	P34S
*52	1039C>T	rs1081003	-
	1661G>C	rs1058164	-
	3877G>A	rs149157808	E418K
	$4180G>C^{f}$	rs1135840	S486T
	4401C>T	rs28371738	-
	1598A>G	rs267608305	-
*53	1611T>A	rs1135822	F120I
	1617G>T	rs1135823	A122S

Allele ^a	Major Nucleotide Variation ^b	dbSNP Number ^c	Effect on CYP2D6
			Protein
	100C>T	rs1065852	P34S
	1039C>T	rs1081003	-
*54	1661G>C	rs1058164	-
	2556C>T	rs267608297	T261I
	4180G>C ^f	rs1135840	S486T
	1661G>C	rs1058164	-
	2850C>T	rs16947	R296C
*55	3790C>T	rs116917064	-
	3835A>C	rs267608285	K404Q
	4180G>C ^f	rs1135840	S486T
	-1584C>G	rs1080985	-
	-1235A>G	rs28735595	-
	-740C>T	rs28624811	-
	-678G>A	rs28633410	-
	<i>CYP2D7</i> gene conversion in intron 1	-	-
*561	1661G>C	rs1058164	-
*30A	2850C>T	rs16947	R296C
	3201C>T	rs147960066	R344X
	3384A>C	rs1985842	-
	3584G>A	rs28371730	-
	3790C>T	rs116917064	-
	$4180G>C^{f}$	rs1135840	[S486T]
	-1426C>T	rs28588594	-
	-1235A>G	rs28735595	-
	-1000G>A	rs1080989	-
	100C>T	rs1065852	P34S
	310G>T	rs28371699	-
	843T>G	-	-
*56B	1039C>T	rs1081003	-
	1661G>C	rs1058164	-
	2097A>G	[rs58440431] ^J	-
	3201C>T	rs147960066	R344X
	3384A>C	rs1985842	-
	3582A>G	rs2004511	-
	$ 4180\text{G} > \text{C}^{\text{t}}$	rs1135840	[S486T]

Allele ^a	Major Nucleotide Variation ^b	dbSNP Number ^c	Effect on CYP2D6
			Protein
	100C>T	rs1065852	P34S
	310G>T	rs28371699	-
	843T>G	-	-
	887C>T	rs267608311	R62W
	1039C>T	rs1081003	-
	1661G>C	rs1058164	-
	3384A>C	rs1985842	-
*57	3582A>G	rs2004511	-
	gene conversion to CYP2D7 in exon 9	-	P469A
		-	T470A
		-	H478S
		_	G479R
		-	F481V
		-	A482S
	$4180G > C^{f}$	rs1135840	[S486T]
	-1426C>T	rs28588594	-
	-1235A>G	rs28735595	-
	-740C>T	rs28624811	-
	CYP2D7 gene conversion in intron 1	-	-
	310G>T	rs28371699	-
	843T>G	_	_
	1023C>T	rs28371706	T107I
*58	1661G>C	rs1058164	-
	1863 1864insTTTCGCCCC	-	174 175insFRP
	2850C>T	rs16947	R296C
	3384A>C	rs1985842	-
	3584G>A	rs28371730	-
	3790C>T	rs116917064	_
	$4180G>C^{f}$	rs1135840	S486T
	1661G>T	rs1058164	-
	2291G>A	rs267608300	_
*59	2850C>T	rs16947	R296C
*39	2939G>A	rs79292917	-
	$4180G > C^{f}$	rs1135840	S486T
	1887insTA	-	S183X
*60	2303C>T	rs79738337	-
	3384A>C	rs1985847	
*61	CYP2D7 sequence from intron 7 onwards	-	_
** - 0	1014C T	-	D 4 41 C
*62	4044C>T	rs/308821/1	K441C

Allele ^a	Major Nucleotide Variation ^b	dbSNP Number ^c	Effect on CYP2D6 Protein
	-1584C>G	rs1080985	_
	-1235A>G	rs28735595	-
	-740C>T	rs28624811	-
	-678G>A	rs28633410	-
	intron 1 conversion with CYP2D7 (214-	-	-
	245)		
	310G>T	rs28371699	-
*63	746C>G	rs28371701	-
	843T>G	-	-
	1661G>C	rs1058164	-
	2850C>T	rs16947	R296C
	3384A>C	rs1985842	-
	3584G>A	rs28371730	-
	3790C>T	rs116917064	-
	CYP2D7 sequence from exon 8 onwards	-	CYP2D7 sequence
	-1426C>T	rs28588594	-
	-1235A>G	rs28735595	-
	-1000G>A	rs1080989	-
	100C>T	rs1065852	P34S
	310G>T	rs28371699	-
	843T>G	-	-
*64	1023C>T	rs28371706	T107I
	1661G>C	rs1058164	-
	2097A>G	[rs58440431] ¹	-
	3384A>C	rs1985842	-
	3582A>G	rs2004511	-
	4180G>C ¹	rs1135840	S486T
	4401C>T	rs28371738	-
	100C>T	rs1065852	P34S
	310G>T	rs28371699	-
	843T>G	-	-
	1661G>C	rs1058164	-
*65	2850C>1	rs16947	R296C
	3384A>C	rs1985842	-
	3584G>A	rs283/1/30	-
	3/90C>1	rs11691/064	- C 40 CT
	41800>C	ISI155840	54801
*66	4401U>A	18110390392	-
.00			
*67	See CYP2D6*13		

Allele ^a	Major Nucleotide Variation ^b	dbSNP Number ^c	Effect on CYP2D6 Protein
	-1426C>T	rs28588594	-
	-1235A>G	rs28735595	-
* < 0 A	-1000G>A	rs1080989	-
*08A	100C>T	rs1065852	P34S
	310G>T	rs28371699	-
	<i>CYP2D7</i> sequence from intron 1 onwards	-	CYP2D7 sequence
* 40D	Similar but not identical switch region		
*08B	compared to CYP2D6*68A		
	-1426C>T	rs28588594	-
	-1235A>G	rs28735595	-
	-1000G>A	rs1080989	-
	100C>T	rs1065852	P34S ^h
	310G>T	rs28371699	-
	746C>G	rs28371701	-
	843T>G	-	-
	1062A>G	rs267608289	-
*69	1661G>C	rs1058164	-
	2850C>T	rs16947	R296C
	2988G>A	rs28371725	Splicing ^h
	3384A>C	rs1985842	-
	3584G>A	rs28371730	-
	3790C>T	rs116917064	-
	$4180G > C^{f}$	rs1135840	S486T
	4401C>T	rs28371738	-
	4481G>A	rs116390392	-
	-176G>A	rs1080993	-
	310G>T	rs28371699	-
	843T>G	-	-
	1608G>A	rs374616348	V119M
	1659G>A, 1661G>C	rs61736512*	V136I
*70		(*for V136M;	
*/0		combined with	
		1661G>C to	
		V136I)	
	3183G>A	rs59421388	V338M
	3384A>C	rs1985842	-
	4180G>C ^f	rs1135840	S486T
	-1584C>G	rs1080985	-
*71	125G>A	rs118203758	G42E
	1494T>C	rs267608306	-

Allele ^a	Major Nucleotide Variation ^b	dbSNP Number ^c	Effect on CYP2D6 Protein
	-1426C>T	rs28588594	-
	-1235A>G	rs28735595	-
	-1000G>A	rs1080989	-
	100C>T	rs1065852	P34S
	310G>T	rs28371699	-
	843T>G	-	-
*70	1039C>T	rs1081003	-
*72	1661G>C	rs1058164	-
	2097A>G	[rs58440431] ^j	-
	3318G>A	rs75386357	E383K
	3384A>C	rs1985842	-
	3582A>G	rs2004511	-
	4180G>C	rs1135840	S486T
	4401C>T	rs28371738	-
	-740C>T	rs28624811	-
	CYP2D7 gene conversion intron 1 (214-	-	-
	245)		
	310G>T	rs28371699	-
	746C>G	rs28371701	-
	843T>G	-	-
*73	1013G>A	rs267608308	V104M
15	1661G>C	rs1058164	-
	2850C>T	rs16947	R296C
	3384A>C	rs1985842	-
	3584G>A	rs28371730	-
	3790C>T	rs116917064	-
	4180G>C ¹	rs1135840	S486T
	4535insT	rs372465406	-
*74	974C>A	rs28371703	L91M
	3609G>T	rs267608322	-
*75	4045G>A	[rs113940699] ⁱ	R441H
*76	See <i>CYP2D6*13</i>		
*77	See CYP2D6*13		
*78	See CYP2D6*13		
*79	See CYP2D6*13		
*80	See CYP2D6*13		
	2579C>T	rs367543000	R269X
*81	2606G>A	[rs77913725] ⁱ	E278K
	2610T>A	rs201830078	M279K

Allele ^a	Major Nucleotide Variation ^b	dbSNP Number ^c	Effect on CYP2D6 Protein
	CVP2D7 gene conversion in evon 2	_	Trotein
	$974C > \Delta$	rs28371703	I 91M
	98/A>G	rs28371703	H9/IR
	997C\G	rs28371704	-
*82		rs76187628	$V10/\Delta$
	$1022 A > T \cdot 1023 C > A$	-	T107Y
	1022A>G	rs78/159009	11071 1109V
	10267>C	$[rs1135821]^{j}$	-
	843T\G	[131133021]	
	gene conversion to CVP2D7 in evon 9	-	- Ρ/69Δ
	gene conversion to CTI 2D7 in exon 3	-	Τ407Α
		-	H478S
*83		-	G470P
		-	E481V
		-	A 482S
	$4180 \text{G} \sim \text{C}^{\text{f}}$	rs1135840	[\$486T]
	-1740C\T	rs58188808	[5+601]
	1235A>G	rs28735505	-
	-1235A>0 740C>T	rs28624811	-
	678A>C	$r_{0}28632410$	-
	18C> A	$r_{0}149392141$	-
	intron 1 conversion with CVP2D7 (214	18140302141	-
	$\frac{1}{245}$	-	-
	243) 310C>T	rs28371600	
	746C\G	$r_{\rm s}28371701$	-
*81	843T\G	1820371701	-
04	1661G\C	rs1058164	_
	2574C	rs1/8769737	- Р267Н
	2374C/A 2850C/T	rs169/7	R206C
	33814	rs10858/12	K270C
	3/016\4	rs267608292	-
	3584G>A	rs28371730	_
	3790C\T	rs11691706/	_
	4180G>C ^f	rs11358/10	- S486T
	4481G>A	rs116390392	-
Allele ^a	Major Nucleotide Variation ^b	dbSNP Number ^c	Effect on CYP2D6 Protein
---------------------	--	---------------------------	-----------------------------
	-1740C>T	rs58188898	-
*85	-1298G>A	rs59099247	-
	-1235A>G	rs28735595	-
	-740C>T	rs28624811	-
	102A>G	rs151226748	-
	310G>T	rs28371699	-
	607G>A	-	-
	746C>G	rs28371701	-
	843T>G	-	-
	1513C>T	rs67497403	-
	1661G>C	rs1058164	-
	2308G>A	-	-
	2850C>T	rs16947	R296C
	3384A>C	rs1985842	-
	3584G>A	rs28371730	-
	3790C>T	rs116917064	-
	4157T>G	-	H478Q
	4180G>C ^r	rs1135840	S486T
*86	2606G>A	[rs77913725] ¹	E278K
00	2610T>A	rs201830078	M279K
	14C>T	-	A5V
	100C>T	rs1065852	P34S
	310G>T	rs28371699	-
*87	843T>G	-	-
	1039C>T	rs1081003	-
	1661G>C	rs1058164	-
	4180G>C ¹	rs1135840	S486T
	746C>G	rs28371701	-
	intron 1 conversion with <i>CYP2D7</i> (214-	-	-
	247)		
	8431>G	-	-
*88	10141>C	rs/618/628	V104A
	1661G>C	rs1058164	-
	3384A>C	rs1985842	-
	3384G>A	rs283/1/30	-
	3/90C>1	rs11691/064	- 0.40 <i>C</i> TT
	4180G>C	rs1135840	54861
*89	1678T>C	rs375135093	L142S
*90	1693A>G	-	K147R
	1735G>C	-	C161S
*91	2850C>T	rs16947	R296C
	2988G>A	rs28371725	Splicing

Allele ^a	Major Nucleotide Variation ^b	dbSNP Number ^c	Effect on CYP2D6 Protein
*92	1995delC	-	Frameshift
*93	2519A>C	-	T249P
	100C>T	rs1065852	P34S
	310G>T	rs28371699	-
*94A	843T>G	-	-
	1039C>T	rs1081003	-
	1661G>C	rs1058164	-
	3181A>G	-	D337G
	$4180G>C^{f}$	rs1135840	S486T
	100C>T	rs1065852	P34S
	843T>G	-	-
*94B	1039C>T	rs1081003	-
	1661G>C	rs1058164	-
	3181A>G	-	D337G
	3384A>C	rs1985842	-
	4180G>C ^f	rs1135840	S486T
	100C>T	rs1065852	P34S
	843T>G	-	-
	1039C>T	rs1081003	-
*95	1661G>C	rs1058164	-
*95	3334G>A	rs77312092	R388H
	3384A>C	rs1985842	-
	4180G>C ^t	rs1135840	S486T
*96	3895C>T	-	Q424X
*97	4094C>A	-	F457L
	746C>G	rs28371701	-
	843T>G	-	-
	intron 1 conversion with CYP2D7(214-	-	-
	247)		
	1661G>C	rs1058164	-
* 9 8	2850C>T	rs16947	R296C
20	3384A>C	rs1985842	-
	3584G>A	rs28371730	-
	3790C>T	rs116917064	-
	4110C>G	-	H463D
	$4180G > C^{f}$	rs1135840	S486T

Allele ^a	Major Nucleotide Variation ^b	dbSNP Number ^c	Effect on CYP2D6 Protoin	
	1426C>T	rc28588501	TIOtem	
*100	1235A>G	rs28735505	-	
	-1233A>O	rs267608271	-	
	-1000G>A	rs1080989	-	
	10003/A	rs1065852	P3/1S	
	310G\T	rs28371699	-	
	843T\G	-	_	
	1039C>T	rs1081003	_	
	1661G>C	rs1058164	-	
	2097A>G	[rs58440431] ^j	_	
	2828C>del	rs267608279	Frameshift	
	3384A>C	rs1985842	-	
	3582A>G	rs2004511	_	
	4180G>C ^f	rs1135840	[S486T]	
	4401C>T	rs28371738	-	
	-1426C>T	rs28588594	-	
	-1235A>G	rs28735595	-	
	-1000G>A	rs1080989	-	
	100C>T	rs1065852	P34S	
	310G>T	rs28371699	-	
	843T>G	-	-	
	1039C>T	rs1081003	-	
*101	1661G>C	rs1058164	-	
	2097A>G	[rs58440431] ^j	-	
	2927_2945GATCCTACATCCGGATGT	rs730882170	Frameshift	
	G>del			
	3384A>C	rs1985842	-	
	3582A>G	rs2004511	-	
	$4180G>C^{t}$	rs1135840	[S486T]	
	4401C>T	rs28371738	-	
	Intron 1 conversion with CYP2D7 (214-	_	_	
	245)	rs28371699	_	
	310G>T	rs267608309	A90V	
	972C>T	rs1058164	-	
*102	1661G>C	rs16947	R296C	
102	2850C>T	rs1985842	-	
	3384A>C	rs116917064	-	
	3790C>T	rs1135840	S486T	
	4180G>C ¹	rs116390392	-	
	4481G>A	101100/00/2		

Allele ^a	Major Nucleotide Variation ^b	dbSNP Number ^c	Effect on CYP2D6 Protein	
	Intron 1 conversion with CYP2D7 (214-	-	-	
	245)			
*103	310G>T	rs28371699	-	
	972C>T	rs267608309	A90V	
	1661G>C	rs1058164	-	
	1749A>G	rs1135824	N166D	
	2850C>T	rs16947	R296C	
	3384A>C	rs1985842	-	
	3790C>T	rs116917064	-	
	$4180 \text{G}>\text{C}^{\text{f}}$	rs1135840	S486T	
	4481G>A	rs116390392	-	
	Intron 1 conversion with CYP2D7 (214-	-	-	
	245)			
	310G>T	rs28371699	-	
	843T>G	-	-	
	1661G>C	rs1058164	-	
*104	1720A>T	-	E156V	
104	2850C>T	rs16947	R296C	
	3384A>C	rs1985842	-	
	3790C>T	rs116917064	-	
	$4180G > C^{t}$	rs1135840	S486T	
	4481G>A	rs116390392	-	
	Intron 1 conversion with CYP2D7 (214-	-	-	
	245)			
	310G>T	rs28371699	-	
	746C>G	rs28371701	-	
	843T>G	-	-	
*105	1661G>C	rs1058164	-	
105	2850C>T	rs16947	R296C	
	3268T>C	-	F366S	
	3384A>C	rs1985842	-	
	3790C>T	rs116917064	-	
	$4180G > C^{t}$	rs1135840	S486T	
	4481G>A	rs116390392	-	

^aSee Human Cytochrome P450 Allele Nomenclature Committee website

(http://www.cypalleles.ki.se) for updated allele information.

^bAll coordinates refer to accession #M33388 as detailed at <u>http://www.cypalleles.ki.se/cyp2d6.htm</u>.

All variants are annotated to the negative DNA strand.

^cRefSNP accession ID number (<u>http://www.ncbi.nlm.nih.gov/snp/</u>).

^dThe *CYP2D6*1* allele is characterized by the absence of any sequence variations. Consequently, this allele cannot be identified by a SNP; rather *CYP2D6*1* is assigned by default when no SNPs are detected during testing.

^eThe *CYP2D6**2 allele is typically characterized by two amino acid changes; both, however also occur in many other *CYP2D6* alleles. Therefore, if an allele carries these two SNPs exclusively, it is designated *CYP2D6**2. Interrogating for additional SNPs is the only way to distinguish *CYP2D6**2 from other alleles (e.g., *CYP2D6**17 and *41).

^fThis SNP is present on many allelic variants including functional and non-functional variants.

Specifically, it has been found on some *CYP2D6*4* subvariants. While some tests include this SNP, it cannot be utilized to identify an allelic variant with certainty.

 $^{g}CYP2D6*2B$ and some other alleles have been defined based on exon sequence only. There may be additional SNPs in introns or flanking regions that are not listed.

^hBoth SNPs in concert have been shown to cause poor metabolizer status in vivo (72).

ⁱrs number has no locus information in dbSNP (dbSNP accessed January 2015).

^jrs number marked as "Suspected" by dbSNP (dbSNP accessed January 2015).

^kThese duplications have been observed (73) but are currently not listed by the nomenclature database.

SUPPLEMENTAL TABLE S2. ASSOCIATION BETWEEN ALLELIC VARIANTS^A AND CYP2D6 ENZYME ACTIVITY

Functional Status (2, 7)	Activity Value ^{c,d}	Alleles
Increased function	>1	*1xN, *2xN, *35xN, *45 ^g xN
Normal or Increased function	$1 \text{ or } > 1^{\mathbf{h}}$	*9xN, *10xN, *17xN, *29xN,
Tronnar of Increased Function	1 01 / 1	*41xN
Normal function ^b	1	*1 ^e , *2, *27, *33, *34 ^f , *35,
	Ĩ	*39 ^f , *45 ^g , *46 ^g , *48, *53
Decreased function	0.5	*9, *10, *14B,*17, *29, *41,
Decreased function	0.5	*49, *50, *54, *55, *59, *72
		*3, *3xN, *4, *4xN, *5, *6,
	0	*6xN, *7, *8, *11, *12, *13,
No-function		*14A, *15, *18, *19, *20, *21,
interiori		*31, *36, *36xN, *38, *40,
		*42, *44, *47, *51, *56, *57,
		*62, *68, *69, *92, *100, *101
		*22, *23, *24, *25, *26, *28,
		*30, *32, *37, *43, *43xN,
		*52, *58, *60, *61, *63, *64,
Unknown	N/A	*65, *70, *71, *73, *74, *75,
CIKIOWI		*81, *82, *83, *84, *85, *86,
		*87, *88, *89, *90, *91, *93,
		*94, *95, *96, *97, *98, *102,
		*103, *104, *105

^aSee <u>http://www.cypalleles.ki.se/cyp2d6.htm</u> for updates on *CYP2D6* allelic variants and nomenclature.

^bAn important caveat for all genotyping tests is that the decision to assign an allele a wild-type status is based upon a genotyping test that interrogates only the most common and already-proven sites of functional variation. It is always possible that a new, previously undiscovered (and therefore un-interrogated) site of variation is defaulted to a functional allele assignment

(wild-type). There is a rare possibility that such variation confers reduced or no activity in an individual and that the person's CYP2D6 function is not accurately predicted.

^cFor some allelic variants there is no or sparse information regarding their activity; therefore no value can be assigned and no CYP2D6 activity score can be calculated. In such cases, the activity score may be estimated based on the second/known allele. A recent in vitro investigation using tamoxifen as substrate provides preliminary information for alleles listed here as unknown (74).

^dFor certain *CYP2D6* alleles *in vivo* data are lacking to unambiguously assign an activity value. For instance, the *CYP2D6*10* and **17* activity values may be substrate dependent, and for particular drugs the activity value could be closer to 1 (normal function) or 0 (no function). It should be noted that the CYP2D6 activity score is a nominal scale. An allele with an activity score of 0.5 does not necessarily have half the metabolic activity of an allele with an activity score of 1. Rather the score of 0.5 indicates the allele has decreased metabolic activity when compared to the *CYP2D6*1* reference allele.

^e*CYP2D6**1 serves as reference and is defined as wild-type.

^f Function of *CYP2D6*34* and **39* is extrapolated from **2*. Both star alleles have SNP(s) that are part of the **2* haplotype.

^gLimited data are available to determine the predicted activity value of *CYP2D6*45* and **46*. Although an activity value of 1 (functional) is assigned to *CYP2D6*45* and **46* in this guideline, others may assign an activity value of 0.5 (reduced function).

^hActivity value is dependent on the number of duplications/multiplications present.

Allele	African	African American	Caucasian (European + North American)	Middle Eastern	East Asian	South/Central Asian	Americas	Oceanian
*1 ^c	32.8	34.0	39	40.7	34.7	45.6	52.0	73.0
*2 ^d	20.1	14.2	28.1	21.7	13.1	32.4	22.9	1.2
*3	0.03	0.3	1.3	0.1	0	0.03	0.6	0
*4	3.4	6.2	18.0	7.8	0.5	7.8	10.7	1.1
*5	6.1	6.1	2.8	2.3	5.2	3.5	1.9	5.0
*6	0	0.2	0.9	0.6	0.02	0	0.4	0
*7	0	0	0.1	0	0	ND	0	0
*8	0	0	0.02	0	0	ND	0.1	0
*9	0.1	0.5	2.1	0	0.1	1.1	1.2	0
*10 ^e	6.8	4.2	2.9	3.5	42.7	14.0	2.8	1.6
*14	0.3	0	0	0.2	0.8	0	0.3	0
*17 ^f	20.0	18.2	0.4	1.6	0.01	0.2	2.3	0.1
*29	10.3	6.5	0.1	0.8	0	0.1	1.4	0
*36	0	0.6	0	0	1.5	ND	0.3	0
*41 ^g	10.9	9.4	7.7	19.9	2.2	12.0	3.9	0

SUPPLEMENTAL TABLE S3. FREQUENCIES^a OF *CYP2D6* ALLELES (IN %) IN MAJOR RACE/ETHNIC GROUPS^b

Allele	African	African American	Caucasian (European + North American)	Middle Eastern	East Asian	South/Central Asian	Americas	Oceanian
xN^h	7.6	4.4	2.7	6.7	1.5	1.6	3.83	8.9
$*1xN^{i}$	1.5	0.4	0.9	3.1	0.3	0.6	0.79	11.8
$*2xN^{i}$	1.6	1.6	1.2	3.9	0.4	1.1	1.84	0
$*4xN^{i}$	1.4	2.1	0.2	0	0	0.2	0.47	0

Abbreviations are as follows: ND = not determined

^aAverage frequencies are based on the actual number of subjects with each allele reported in multiple studies. For full details and references please see <u>http://www.pharmgkb.org/download.action?filename=CYP2D6_Frequency_Table_and_Legend_R3.pdf</u>. ^bWorldwide race/ethnic designations correspond to the Human Genome Diversity Project- Centre d'Etude du Polymorphisme Humain (HGDP-CEPH) (75, 76).

^cBecause *CYP2D6*1* is not genotyped directly, all alleles that are negative for a sequence variation are defaulted to a *CYP2D6*1* assignment. Likewise, sequence variations of alleles that are not tested may default to a *CYP2D6*1* assignment and hence contribute to the frequencies reported for this allele. Therefore, the inferred frequency for *CYP2D6*1* was calculated as an average from studies describing allele frequencies for the most common alleles found in a particular ethnic group. Studies not describing a frequency for *2 or few allelic variants (*4 and *5 only, or *10 only, for example) were omitted for the estimation of *1.

^d*CYP2D6**2 is a 'default' assignment and, unless tested and discriminated for *CYP2D6**8, *11, *17, *35, *41 and other variants, will default to a *CYP2D6**2 assignment. The frequencies shown here may therefore be over-estimated.

^e*CYP2D6*10* is a 'default' assignment and, unless tested and discriminated for, *CYP2D6*14* and *36 and other variants, will default to a *CYP2D6*10* assignment. The frequencies shown here may therefore be over-estimated.

^fCYP2D6*17 is a 'default' assignment and, unless tested and discriminated for, CYP2D6*40 and *58 will default to a CYP2D6*17

assignment. The frequencies shown here may therefore be over-estimated.

^g*CYP2D6*41* has not consistently been determined by its defining SNP (2988G>A) across studies; some platforms still use the -1584C>G SNP to discriminate between *CYP2D6*2* and **41*. This may lead to an overestimation of the *CYP2D6*41* frequency, especially in those of African ancestry (77).

^hxN denotes all gene duplications regardless of their nature. Alleles reported as CYP2D6*2xN, but not specifically discriminated from other duplications such as CYP2D6*1xN or *4xN were tabulated as xN.

¹Frequencies calculated only from those studies which discriminated between gene duplications, that is studies that specified duplications such as *CYP2D6*1xN*, *2*xN*, or *4*xN* were present. Because there may have been other duplications present and fewer studies had data for differentiated gene duplications, the sum of *CYP2D6*1xN*, *2*xN*, and *4*xN* is less than the sum shown for *xN*. *xN* may also contain other alleles with gene rearrangements that test positive in a duplication assay, but do not carry duplications of identical gene units.

Note: Diplotype frequencies of interest can be estimated using the equation describing Hardy Weinberg equilibrium. For example, the probability of observing an African American individual with a homozygous CYP2D6*1/*1 diplotype is p^2 (0.3397*0.3397=0.115 or 11.5%). The probability for subjects to be heterozygous for the CYP2D6*1/*5 diplotype is 2pq (2*0.3397*0.0614 = 0.042 or 4.2%) and subjects to be homozygous for CYP2D6*5/*5 is q^2 (0.0614*0.0614 = 0.0038 or 0.38%). To translate respective diplotypes into its phenotype, see the translation table available at PharmGKB (<u>https://www.pharmgkb.org/guideline/PA166127636</u> or <u>https://www.pharmgkb.org/guideline/PA166127637</u>).

SUPPLEMENTAL TABLE S4. GENOTYPES THAT MAINLY CONSTITUTE THE STAR (*) ALLELES FOR *CYP2C19* AND THEIR EFFECT ON CYP2C19 PROTEIN

Allele ^a	Major Nucleotide Variation ^{b,c}	dbSNP Number ^d	Effect on CYP2C19 Protein
*1	-	-	-
*2	19154G>A	rs4244285	Splicing defect
*3	17948G>A	rs4986893	W212X
*4A ^e	1A>G	rs28399504	M1V
*4B ^e	-806C>T 1A>G	rs12248560 rs28399504	M1V
*5	90033C>T	rs56337013	R433W
*6	12748G>A	rs72552267	R132Q
*7	19294T>A	rs72558186	Splicing defect
*8	12711T>C	rs41291556	W120R
*9	12784G>A	rs17884712	R144H
*10	19153C>T	rs6413438	P227L
*11	12802G>A	rs58973490	R150H
*12	90209A>C	rs55640102	X491C (26 extra aa)
*13	87290C>T	rs17879685	R410C
*14	50T>C	rs55752064	L17P
*15	55A>C	rs17882687	I19L
*16	90060C>T	rs192154563	R442C
*17 ^e	-806C>T	rs12248560	-
n/a ^f	-806C>T c.463G>T	rs12248560 rs374036992	- E155X
*18	80156G>A 87106T>C	rs138142612 rs4917623	R329H
*19	151A>G 87106T>C	- rs4917623	\$51G
*22	17869G>C	rs140278421	R186P
*23	12455G>C	rs118203756	G91R
*24	80174G>A 87259A>G	rs118203757 -	R335Q

Allele ^a	Major Nucleotide Variation ^{b,c}	dbSNP Number ^d	Effect on CYP2C19 Protein
*25	90080C>G	rs118203759	F448L
*26	19239G>A	-	D256N
*27	-1041G>A	-	-
*28	-2030C>T -2020C>A -1439T>C 55A>C 80290G>A	rs113164681 rs111490789 rs17878739 rs17882687 rs113934938	- - I19L V374I
*29	83A>T	-	K28I
*30	12401C>T ^g	rs145328984	R73C
*31	12416C>T	-	H78Y
*32	12480A>G	-	H99R
*33	17874G>A	rs370803989	D188N
*34	-13G>A 7C>T 10T>C	- rs367543002 rs367543003	- P3S F4L

^aSee Human Cytochrome P450 Allele Nomenclature Committee website

(http://www.cypalleles.ki.se) for comprehensive haplotype definitions of *CYP2C19* variant alleles and updated allele information.

^bAll coordinates refer to GenBank *CYP2C19* sequence NT_030059.13⁺ as detailed at <u>http://www.cypalleles.ki.se/cyp2c19.htm</u>. All variants are annotated to the positive DNA strand. (⁺To be considered *CYP2C19*1A*, the genomic reference sequence must be changed to -1041G, 99C and 80161A).

^cSome of the alleles may carry multiple nucleotide variations. More specific details on the combinations of SNPs present in each allele can be found at http://www.cypalleles.ki.se. In addition, the specific SNPs included

in the genotyping assays can be found in the assays' product inserts.

^dRefSNP accession ID number (<u>http://www.ncbi.nlm.nih.gov/snp/</u>).

^eThe detrimental *CYP2C19*4*-defining SNP (rs28399504) has been identified to be linked (i.e. on the same chromosome) with *17 (-806C>T; rs12248560) in certain ethnic subpopulations. This haplotype is designated *CYP2C19*4B* (1, 40). To distinguish the *4 (no function) and *17

(increased function) alleles, both rs28399504 and rs12248560 should be genotyped (40, 42)). ^fA novel SNP (c.463G>T) has been identified to occur in linkage with the *17-defining SNP (-806C>T; rs12248560). This allele has not been assigned a separate star (*) designation by the Nomenclature Committee. To distinguish *17 from this novel haplotype, c.463G>T needs to be genotyped (41).

SUPPLEMENTAL TABLE S5. ASSOCIATION BETWEEN ALLELIC VARIANTS AND CYP2C19 ENZYME ACTIVITY

Functional Status	Alleles
Increased function	*17
Normal function ^a	*1, *11, *13, *15, *18, *28
Decreased function	*9, *10, *16, *19, *25, *26
No function	*2, *3, *4, *5, *6, *7, *8, *22, *24
Unknown	*12, *14, *23, *27, *29, *30, *31, *32,
Chkhown	*33, *34

^aAn important caveat for all genotyping tests is that the decision to assign an allele a wild-type status is based upon a genotyping test that interrogates only the most common and already-proven sites of functional variation. It is always possible that a novel, previously undiscovered (and therefore un-interrogated) site of variation may confer loss-of-function in an individual, and thus lead to the rare possibility of a non-functional allele being erroneously called as wild-type.

Allele	African	African American	Caucasian (European + North American)	Middle Eastern	East Asian	South/Central Asian	Americas	Oceanian
*1 ^c	36.4	58.1	62.1	84.2	58.0	47.4	69.0	28.6
*2	14.2	18.3	14.6	13.2	29.0	34.4	13.1	54.9
*3	0.8	0.3	0.6	2.6	8.5	1.7	0.3	13.9
*4 ^d	0	0	0.4	ND	0.1	0	0.03	ND
*5	0	0	0	ND	0	0	0	ND
*6	0	0	0.1	ND	0.03	0	0	ND
*8	0	0.2	0.3	ND	0	0	0.1	ND
*17	15.1	19.4	21.5	ND	1.6	16.5	16.3	2.5

SUPPLEMENTAL TABLE S6. FREQUENCIES^a OF CYP2C19 ALLELES (IN %) IN MAJOR RACE/ETHNIC GROUPS^b

Abbreviations are as follows: ND = not determined

For full details and references please

http://www.pharmgkb.org/download.action?filename=CYP2C19_Frequency_Table_and_Legend_V1.pdf.

^aAverage frequencies are based on the actual number of subjects with each allele as reported in one or multiple studies.

^bWorldwide race/ethnic designations correspond to the Human Genome Diversity Project- Centre d'Etude du Polymorphisme Humain (HGDP-CEPH) (75, 76).

^cBecause CYP2C19*1 is not genotyped directly, all alleles that are negative for a sequence variation are defaulted to a CYP2C19*1

assignment. The inferred frequency for *CYP2C19*1* is calculated as: 100 - (sum of averaged variant allele frequencies).

^{*d}</sup><i>CYP2C19*4A* and **4B* allele frequencies were combined.</sup>

Note: Diplotype frequencies of interest can be estimated using the equation describing Hardy Weinberg equilibrium. For example, the probability of observing an African American individual with a homozygous CYP2C19*1/*1 diplotype is p^2 (0.5809*0.5809=0.337 or 33.7%). The probability for subjects to be heterozygous for the CYP2C19*1/*2 diplotype is 2pq (2*0.5809*0.1833 = 0.213 or 21.3%) and subjects to be homozygous for CYP2C19*2/*2 is q^2 (0.0.1833*0.1833 = 0.034 or 3.4%). To translate respective diplotypes into its phenotype, see the translation table available at PharmGKB (link will be added once/if manuscript accepted).

SUPPLEMENTAL TABLE S7. EVIDENCE LINKING CYP2D6 GENOTYPE TO FLUVOXAMINE PHENOTYPE

CYP2D6 -Fluvoxamine					
Experimental	Major Findings	Level of			
model			Evidence		
Clinical	Higher risk of developing gastrointestinal side effects in patients	Suzuki <i>et al</i> . 2006 (78)	Moderate		
	with reduced CYP2D6 activity (*1/*5; *10/*10; *5/*10) compared				
	to normal metabolizers (* $1/*1$; * $1/*10$).				
Clinical	Patients with two variant CYP2D6 alleles (CYP2D6*5/CYP2D6*10	Suzuki <i>et al</i> . 2011 (79)	Moderate		
	and <i>CYP2D6*10/CYP2D6*10</i>) had significantly higher				
	fluvoxamine plasma concentrations compared to patients with no				
	variant alleles.				
Clinical	Phenotypic CYP2D6 PMs (healthy volunteers (80) and patients	Carrillo <i>et al</i> . 1996 (80)	Moderate		
	(81) had significantly different fluvoxamine pharmacokinetic	Spigset <i>et al.</i> 1997 (81)			
	parameters (higher maximum plasma concentration, longer half-				
	life, or lower oral clearance of fluvoxamine) following a single				
	dose as compared to EMs.				
Clinical	Phenotypic CYP2D6 PMs (healthy volunteers) had a lower	Spigset <i>et al.</i> 2001 (82)	Weak		
	clearance than EMs following a single dose of fluvoxamine.				
Clinical	Patients with at least one variant <i>CYP2D6</i> allele had significantly	Watanabe et al. 2008	Weak		
	higher fluvoxamine plasma levels than CYP2D6 wild-type patients	(83)			
	under steady state conditions with lower doses of fluvoxamine				
	(50mg) but not higher doses (100-200mg).				

CYP2D6 -Paroxetine					
Experimental model	Major findings	Reference	Level of evidence		
Clinical	Genotypic CYP2D6 UMs (patients (58, 59, 84) and health	Güzey et al. 2006 (59)	High		
	volunteers (57)) had significantly lower, or undetectable,	Lam <i>et al</i> . 2002 (57)			
	paroxetine plasma concentrations at steady state when compared	Charlier <i>et al.</i> 2003 (84)			
	to genotypic EMs.	Gex-Fabry et al. 2008 (58)			
Clinical	Genotypic CYP2D6 UMs (patients) did not have an	Güzey et al. 2006 (59)	Weak		
	antidepressant response to paroxetine.	Gex-Fabry et al. 2008 (58)			
Clinical	A subset of individuals determined to be CYP2D6 EMs by	Sindrup <i>et al.</i> 1992 (85)	Moderate		
	genotyping/phenotyping may phenocopy after prolonged	Zourková et al. 2003 (86)			
	paroxetine treatment.	Lam <i>et al</i> . 2002 (57)			
		Solai <i>et al</i> . 2002 (87)			
Clinical	CYP2D6 UMs may not phenocopy (convert to a PM phenotype) when administered paroxetine.	Lam <i>et al</i> . 2002 (57)	Weak		
Clinical	Healthy volunteers determined to be CYP2D6 PMs by	Charlier <i>et al.</i> 2003 (84)	High		
	genotyping or phenotyping had significantly higher paroxetine	Sindrup <i>et al.</i> 1992 (85)	U		
	plasma concentrations at steady state compared to EMs.				
Clinical	Individuals (healthy volunteers (85) and patients (88))	Findling <i>et al.</i> 1999 (88)	Moderate		
	determined to be CYP2D6 PMs by genotyping/phenotyping had	Sindrup <i>et al.</i> 1992 (85)			
	significantly different pharmacokinetic parameters (e.g., lower				
	clearance, greater AUC and half-life) of paroxetine versus EMs.				
Clinical	Pharmacokinetic parameters at steady state were significantly	Feng et al. 2006 (89)	High		
	different among those with 0, 1, 2, or >2 active <i>CYP2D6</i> alleles.	Findling <i>et al.</i> 2006 (90)			
	Those with the most active alleles had the lowest paroxetine	Sawamura <i>et al.</i> 2004 (91)			
	concentrations and those with no active alleles had the highest	Van Nieuwerburgh et al. 2009 (92)			
	paroxetine concentrations.	Saruwatari et al.(93)			
Clinical	Significant relationship between paroxetine-induced adverse	Zourkova et al. 2007 (94)	Weak		
	drug reactions observed when female CYP2D6 PMs were				
	compared to female EMs.				
Clinical	Suspected adverse effects due to paroxetine intoxication in a	Sato et al. 2004 (95)	Weak		
	genotypic CYP2D6 IM.				
Clinical	No significant relationship between paroxetine-induced adverse	Murphy et al. 2003 (96)	Weak		
	drug reactions was observed when genotypic CYP2D6 PMs	Stedman et al. 2002 (97)			
	and/or IMs were compared to EMs.	Sugai <i>et al.</i> 2006(98)			

SUPPLEMENTAL TABLE S8. EVIDENCE LINKING CYP2D6 GENOTYPE TO PAROXETINE PHENOTYPE

SUPPLEMENTAL TABLE S9. EVIDENCE LINKING CYP2C19 AND CYP2D6 GENOTYPE TO

CITALOPRAM/ESCITALOPRAM PHENOTYPE

CYP2C19 and CYP2D6-Citalopram/Escitalopram					
Experimental model	Major findings	Reference	Level of Evidence		
Clinical	Genotypic CYP2C19 PMs (patients) had significantly higher racemic citalopram or escitalopram plasma concentrations at steady state as compared to the median dose-corrected plasma concentrations of all study participants.	Grasmader <i>et al.</i> 2004 (99) de Vos <i>et al.</i> 2011 (15) Huezo-Diaz <i>et al.</i> 2012 (100) Rudberg <i>et al.</i> 2008 (101) Tsai <i>et al.</i> 2010 (102)	High		
Clinical	Individuals (healthy volunteers (103, 104) and patients (105))determined to be CYP2C19 PMs by genotyping or phenotyping had significantly different pharmacokinetic parameters (higher citalopram or escitalopram plasma concentrations, higher AUC, longer half-life, or slower clearance) at steady state as compared to EMs.	Herrlin <i>et al.</i> 2003 (103) Noehr-Jensen <i>et al.</i> 2009 (104) Yin <i>et al.</i> 2006 (105)	High		
Clinical	Healthy volunteers determined to be CYP2C19 PMs by genotyping or phenotyping had significantly higher escitalopram AUC, half-life, or lower clearance after a single dose of escitalopram as compared to EMs.	Noehr-Jensen <i>et al.</i> 2009 (104) Fudio <i>et al.</i> 2010 (106) Yu <i>et al.</i> 2003 (107)	Moderate		
Clinical	Genotypic CYP2C19 IMs (patients (101) and healthy volunteers (106, 108) had significantly higher citalopram or escitalopram plasma concentrations or AUC when compared to EMs.	Rudberg <i>et al.</i> 2008 (101) Fudio <i>et al.</i> 2010 (106) Chen <i>et al.</i> 2013 (108)	High		
Clinical	Patients carrying a <i>CYP2C19*17</i> allele had significantly lower levels of citalopram or escitalopram.	Rudberg <i>et al.</i> 2008 (101) Hodgson <i>et al.</i> 2014 (109) de Vos <i>et al.</i> 2011 (15) Huezo-Diaz <i>et al.</i> 2012 (100)	Moderate		
Clinical	Patients with a <i>CYP2C19</i> *17/*17 genotype had significantly lower citalopram or escitalopram plasma concentrations at steady state when compared to EMs.	Huezo-Diaz <i>et al.</i> 2012 (100) Rudberg <i>et al.</i> 2008 (101) Hodgson <i>et al.</i> 2014 (109) Rosenborg <i>et al.</i> 2008 (110)	High		

Experimental model	Major findings	Reference	Level of Evidence
Clinical	CYP2C19 PMs and IMs may be at greater risk of citalopram- induced prolonged QT interval. No association between escitalopram-induced prolonged QT interval and CYP2D6 phenotype.	Kumar <i>et al</i> . 2014(111)	Moderate
Clinical	CYP2C19 PM (determined by genotyping or phenotyping) associated with decreased tolerance.	Mrazek <i>et al.</i> 2011 (112) Herrlin <i>et al.</i> 2003 (103) Yin <i>et al.</i> 2006 (105)	Weak
Clinical	CYP2C19 PM (determined by genotyping) associated with better response or remission.	Mrazek <i>et al.</i> 2011 (112) Hodgson <i>et al.</i> 2014 (113)	Weak
Clinical	CYP2C19 PM (determined by genotyping) not associated with better response or remission.	Hodgson <i>et al.</i> 2014 (109) Peters <i>et al.</i> 2008 (114) Tsai <i>et al.</i> 2010 (102)	
Clinical	Side effects observed in a patient determined by phenotyping to be both a CYP2D6 PM and CYP2C19 PM.	Herrlin et al. 2003 (103)	Weak
Clinical	Genotypic CYP2D6 PMs (patients) had significantly higher citalopram or escitalopram plasma concentrations at steady state when compared to EMs.	Grasmader <i>et al.</i> 2004 (99) Herrlin <i>et al.</i> 2003 (103) Huezo-Diaz <i>et al.</i> 2012 (100) Tsai <i>et al.</i> 2010 (102)	Weak
Clinical	Genotypic CYP2D6 IMs (patients) had significantly higher citalopram or escitalopram plasma concentrations at steady state when compared to EMs.	Huezo-Diaz et al. 2012 (100)	Weak
Clinical	Relationship between genotypic CYP2D6 IM/PM status and better/faster response (tolerance and remission).	Mrazek <i>et al.</i> 2011 (112) Tsai <i>et al.</i> 2010 (102) Han <i>et al.</i> 2013(115)	Weak
Meta-analysis	Meta-analysis included a total 847 patients from psychiatric patient trials and 140 healthy subjects from pharmacokinetic studies. CYP2C19 PMs (*2 or *3/*2 or *3) had increased exposure to (es)citalopram by 95 %, IMs (*1/*2 or *3) by 30 %, IMs (*17/*2 or *3) by 25 % compared to EMs (*1/*1). Subjects with CYP2C19*17/*17 had decreased exposure by 36 % and CYP2C19*17/*1 by 14 % compared to EM (*1/*1).	Chang <i>et al.</i> 2014 (116)	High

	CYP2D6 -Fluoxetine		
Type of	Major findings	Reference	Level of
model			Evidence
Clinical	Patients determined to be CYP2D6 PMs by genotyping or phenotyping	Charlier <i>et al.</i> 2003 (84)	High
	had significantly higher fluoxetine plasma concentrations at steady as	Eap et al. 2001 (117)	
	compared to EMS.		
Clinical	Phenotypic CYP2D6 PMs (healthy volunteers) had significantly	Fjordside <i>et al</i> . 1999 (52)	High
	different fluoxetine pharmacokinetic parameters (lower clearance,	Hamelin <i>et al.</i> 1996 (118)	
	greater AUC and half-life) following a single dose as compared to EMs.		
Clinical	Steady-state fluoxetine dose-corrected plasma concentrations were	Llerena et al. 2004 (8)	High
	significantly different among patients with 0, 1, 2, or >2 active CYP2D6		
	alleles. Subjects with the most active alleles had the lowest fluoxetine		
	concentrations and those with no active alleles had the highest		
	fluoxetine concentrations.		
Clinical	Fluoxetine/(S)-norfluoxetine ratio is negatively correlated with the	Gasso et al. 2014 (119)	Moderate
	number of normal function CYP2D6 alleles		
Clinical	Suspected adverse effects and eventual death due to fluoxetine	Sallee <i>et al.</i> 2000 (120)	Weak
	intoxication in a genotypic CYP2D6 PM.		
Clinical	No significant relationship between fluoxetine-induced adverse drug	Roberts et al. 2004 (121)	Moderate
	reactions and CYP2D6 PMs and EMs determined by genotyping.		

SUPPLEMENTAL TABLE S10. EVIDENCE LINKING CYP2D6 GENOTYPE TO FLUOXETINE PHENOTYPE

SUPPLEMENTAL TABLE S11. EVIDENCE LINKING CYP2C19 GENOTYPE TO SERTRALINE PHENOTYPE

	CYP2C19 -Sertraline		
Type of experimental model	Major findings	Reference	Level of Evidence
Clinical	Genotypic CY2C19 PMs (patients carrying two defective <i>CYP2C19</i> alleles) had higher sertraline plasma concentrations at steady state compared to EM patients with a <i>CYP2C19*1/*1</i> Genotype.	Rudberg <i>et al.</i> 2008 (122)	Moderate
Clinical	Healthy volunteers determined to be CYP2C19 PMs by phenotyping and genotyping had significantly different sertraline pharmacokinetic parameters (<i>i.e.</i> higher area under the plasma concentration versus time curve and longer half-life, lower clearance) after one dose of sertraline compared to EMs (<i>CYP2C19*1/*1</i> and <i>*1/null</i>).	Wang <i>et al.</i> 2001 (123)	Moderate
Clinical	Sertraline-induced adverse effects observed in CYP2C19 PMs (determined by phenotyping).	Wang et al. 2001 (123)	Weak



CPIC Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of SSRIs – Supplemental v1.0

SUPPLEMENTAL TABLE S12. DRUGS ASSOCIATED WITH GENE-BASED DOSING RECOMMENDATIONS IN THIS GUIDELINE.

Drug or Ingredient	Source	Code Type	Code
Citalopram	RxNorm	RxCUI	C0008845
Citalopram	DrugBank	Accession Number	DB00215
Citalopram	ATC	ATC Code	N06AB04
Citalopram	PharmGKB	PharmGKB ID	PA449015
Escitalopram	RxNorm	RxCUI	C1099456
Escitalopram	DrugBank	Accession Number	DB01175
Escitalopram	ATC	ATC Code	N06AB10
Escitalopram	PharmGKB	PharmGKB ID	PA10074
Fluvoxamine	RxNorm	RxCUI	C0085228
Fluvoxamine	DrugBank	Accession Number	DB00176
Fluvoxamine	ATC	ATC Code	N06AB08
Fluvoxamine	PharmGKB	PharmGKB ID	PA449690
Paroxetine	RxNorm	RxCUI	C0070122
Paroxetine	DrugBank	Accession Number	DB00715
Paroxetine	ATC	ATC Code	N06AB05
Paroxetine	PharmGKB	PharmGKB ID	PA450801
Sertraline	RxNorm	RxCUI	C0074393
Sertraline	DrugBank	Accession Number	DB01104
Sertraline	ATC	ATC Code	N06AB06
Sertraline	PharmGKB	PharmGKB ID	PA451333

SUPPLEMENTAL TABLE S13. GENES THAT PERTAIN TO THIS GUIDELINE

Gene Symbol	Source	Code Type	Code
СҮР2С19	HGNC	Symbol	CYP2C19
СҮР2С19	HGNC	HGNC ID	HGNC:2621
СҮР2С19	NCBI	Gene ID	1557
СҮР2С19	Ensembl	Ensembl ID	ENSG00000165841
СҮР2С19	PharmGKB	PharmGKB ID	PA124
CYP2D6	HGNC	Symbol	CYP2D6
CYP2D6	HGNC	HGNC ID	HGNC:2625
CYP2D6	NCBI	Gene ID	1565
CYP2D6	Ensembl	Ensembl ID	ENSG00000100197
CYP2D6	PharmGKB	PharmGKB ID	PA128



Blue shading indicates interaction with provider

SUPPLEMENTAL FIGURE S2. *CYP2D6/CYP2C19* PHARMACOGENETIC TEST RESULT: CLINICAL IMPLEMENTATION WORKFLOW FOR EHR

^aSee Supplementary Table S14 (CYP2D6) and S15 (for CYP2C19) for diplotype/phenotype specific examples

^bPriority result is defined as a genetic test result that necessitates a change in drug, drug dose, or drug monitoring now or potentially in the future.

^cDocumentation in the EHR is institution specific. Optimally, the phenotype and/or genotype are available in the EHR to permanently inform prescribing decisions. See **Supplementary Tables S14** (CYP2D6) and **S15** (for CYP2C19) for genotype/phenotype-specific summaries.

^d*CYP2D6/CYP2C19* genetic testing is most helpful prior to initiation of the drug. However, in some cases (e.g., patient experiencing side effects, current drug therapy ineffective) *CYP2D6/CYP2C19* genetic results might be useful in choosing alternative therapy.



SUPPLEMENTAL FIGURE S3. *CYP2D6/CYP2C19* GENOTYPE AND SSRI: POINT OF CARE CLINICAL DECISION SUPPORT

^aSee **Supplementary Table S16** for diplotype/phenotype specific pre-test alert examples.

^bAdditional actions may include ordering a pharmacogenetic test, preventing the clinician from ordering the medication or allowing the clinician to cancel out of the alert.

^cPriority result is defined as a genetic test result that necessitates a change in drug, drug dose, or drug monitoring now or potentially in the future.

^dSee **Supplementary Table S16** for diplotype/phenotype specific post-test alert examples.

SUPPLEMENTAL TABLE S14. EXAMPLE IMPLEMENTATION OF THIS GUIDELINE FOR CYP2D6:

PHARMACOGENETIC DIPLOTYPE/PHENOTYPE SUMMARY ENTRIES^a

Allele definition	CYP2D6 Activity Score	Coded Diplotype/Phenotype Summary ^b	EHR Priority Result Notation ^c	Consultation (Interpretation) Text Provided with Test Result ^d
An individual carrying duplications of normal function alleles	> 2	CYP2D6 Ultrarapid Metabolizer	Abnormal/Pri ority/High Risk	This result signifies that this patient has more than two copies of a normal function allele. Based on the genotype result this patient is predicted to be an ultrarapid metabolizer of CYP2D6 substrates. This patient may be at risk for an adverse or poor response to medications that are metabolized by CYP2D6. To avoid an untoward drug response, dose adjustments may be necessary for medications metabolized by CYP2D6. Please consult a clinical pharmacist for more information about how CYP2D6 metabolic status influences drug selection and dosing.
An individual carrying a duplicated normal function allele and a decreased function allele	> 2	CYP2D6 Ultrarapid Metabolizer	Abnormal/Pri ority/High Risk	This result signifies that this patient has two copies of normal function allele (*_xN) ^e and one copy of a reduced function allele (*_). Based on the genotype result this patient is predicted to be an ultrarapid metabolizer of CYP2D6 substrates. This patient may be at risk for an adverse or poor response to medications that are metabolized by CYP2D6. To avoid an untoward drug response, dose adjustments may be necessary for medications metabolized by CYP2D6. Please consult a clinical pharmacist for more information about how CYP2D6 metabolic status influences drug selection and dosing.

Allele	CYP2D6	Coded	EHR Priority	Consultation (Interpretation) Text Provided with
definition	Activity	Diplotype/Phenotype	Result	Test Result ^d
	Score	Summary ²	Notation ²	
An individual		None	Normal/Routi	This result signifies that the patient has two copies of a
carrying two			ne/ Low Kisk	normal function allele. Based on the genotype result
normal function				this patient is predicted to be an extensive (normal)
alleles	2.0			metabolizer of CYP2D6 substrates. There is no reason
				to selectively adjust the dose of most medications that
				are metabolized by CYP2D6. Please consult a clinical
				pharmacist for more information about how CYP2D6
				metabolic status influences drug selection and dosing.
An individual		None	Normal/Routi	This result signifies that this patient has one copy of a
carrying one			ne/ Low R1sk	normal function allele (*_) and two copies of a reduced
normal function				function allele $(*_xN)^{\sim}$. Based on the genotype result
allele and a				this patient is predicted to be an extensive (normal)
duplicated	2.0			metabolizer of CYP2D6 substrates. There is no reason
decreased				to selectively adjust the dose of most medications that
function allele				are metabolized by CYP2D6. Please consult a clinical
				pharmacist for more information about how CYP2D6
	 			metabolic status influences drug selection and dosing.
An individual		None	Normal/Routi	This result signifies that the patient has one copy of a
carrying one			ne/ Low R1sk	normal function allele ($*$ _) and one copy of a decreased
normal function				function allele (*_). Based on the genotype result this
and one	1 7			patient is predicted to be an extensive (normal)
decreased	1.5			metabolizer of CYP2D6 substrates. There is no reason
function allele				to selectively adjust the dose of most medications that
				are metabolized by CYP2D6Please consult a clinical
				pharmacist for more information about how CYP2D6
				metabolic status influences drug selection and dosing.

Allele	CYP2D6	Coded	EHR Priority	Consultation (Interpretation) Taxt Provided with
definition	Activity	Diplotype/Phenotype	Result	Tost Posult ^d
	Score	Summary ^b	Notation ^c	Test Result
An individual		None	Normal/Routi	This result signifies that this patient two copies of a
carrying one			ne/ Low Risk	decreased function allele (*_xN) ^e and one copy of a
duplicated				reduced function allele (*_). Based on the genotype
decreased				result this patient is predicted to be an extensive
function allele	15			(normal) metabolizer of CYP2D6 substrates. There is
and one	1.5			no reason to selectively adjust the dose of most
decreased				medications that are metabolized by CYP2D6Please
function allele				consult a clinical pharmacist for more information
				about how CYP2D6 metabolic status influences drug
				selection and dosing.
An individual		None	Normal/Routi	This result signifies that the patient has two copies of a
carrying two			ne/ Low Risk	decreased function allele. Based on the genotype result
decreased				this patient is predicted to be an extensive (normal)
function alleles	1.0			metabolizer of CYP2D6 substrates. There is no reason
				to selectively adjust the dose of most medications that
				are metabolized by CTP2D0. Please consult a clinical
				metabolic status influences drug selection and dosing
An individual		None		This result signifies that the patient has one copy of a
carrying one		TYONE		normal function allele (*) and one copy of a no
normal function				function allele (*) Based on the genotype result this
and one no				patient is predicted to be an extensive (normal)
function allele	1.0			metabolizer of CYP2D6 substrates. There is no reason
				to selectively adjust the dose of most medications that
				are metabolized by CYP2D6. Please consult a clinical
				pharmacist for more information about how CYP2D6
				metabolic status influences drug selection and dosing.

Allele	CYP2D6	Coded	EHR Priority	Congultation (Interpretation) Toxt Provided with
definition	Activity	Diplotype/Phenotype	Result	Consumation (Interpretation) Text Provided with
	Score	Summary ^b	Notation ^c	l est kesuit
An individual		None	Normal/Routi	This result signifies that the patient has two copies of a
carrying one no			ne/ Low Risk	reduced function allele (*_xN) ^e and one copy of a no
function allele				function allele (*_). Based on the genotype result this
and a duplicated				patient is predicted to be an extensive (normal)
decreased	1.0			metabolizer of CYP2D6 substrates. There is no reason
function allele				to selectively adjust the dose of most medications that
				are metabolized by CYP2D6. Please consult a clinical
				pharmacist for more information about how CYP2D6
				metabolic status influences drug selection and dosing.
An individual		CYP2D6 Intermediate	Abnormal/Pri	This result signifies that the patient has one copy of a
carrying one		Metabolizer	ority/High	decreased function allele (*_) and one copy of a no
decreased			Risk	function allele (*_). Based on the genotype result this
function and one				patient is predicted to be an intermediate metabolizer of
no function				CYP2D6 substrates. This patient may be at risk for an
allele	0.5			adverse or poor response to medications that are
	0.5			metabolized by CYP2D6. To avoid an untoward drug
				response, dose adjustments may be necessary for
				medications metabolized by CYP2D6. Please consult a
				clinical pharmacist for more information about how
				CYP2D6 metabolic status influences drug selection and
				dosing.

Allele definition	CYP2D6 Activity Score	Coded Diplotype/Phenotype Summary ^b	EHR Priority Result Notation ^c	Consultation (Interpretation) Text Provided with Test Result ^d
An individual		CYP2D6 Poor	Abnormal/Pri	This result signifies that the patient has two copies of a
carrying only no		Metabolizer	ority/High	no function allele. Based on the genotype result this
functional			Risk	patient is predicted to be a poor metabolizer of
alleles				CYP2D6 substrates. This patient may be at a high risk
				for an adverse or poor response to medications that are
	0			metabolized by CYP2D6. To avoid an untoward drug
				response, dose adjustments or alternative therapeutic
				agents may be necessary for medications metabolized
				by the CYP2D6. Please consult a clinical pharmacist
				for more information about how CYP2D6 metabolic
				status influences drug selection and dosing.

This table is provided to show examples of how a test result could be translated into discrete fields within an EHR, including a brief interpretation that summarizes the result. The information presented here is consistent with the guideline but may need to be adapted to a given EHR's design and capabilities. Because various EHRs or organizations may require different terms different options are provided.

^aA more comprehensive table of genotype/phenotype EHR entries for possible diplotype combinations of all variants listed in

Supplemental Table S2 is available at PharmGKB (<u>https://www.pharmgkb.org/guideline/PA166127636</u> or

https://www.pharmgkb.org/guideline/PA166127637).

^bThe coded diplotype/phenotype summary is used to store an interpretation of the test result. This is a design decision that may differ among sites. Assignment of all Genotype/Phenotype Summaries based on diplotype is available at

(https://www.pharmgkb.org/guideline/PA166127636 or https://www.pharmgkb.org/guideline/PA166127637).

^cFor this example, a priority result is defined as a genetic test result that results in a change in drug, drug dose, or drug monitoring.

^dThe specific wording of the interpretive text may differ among sites.

^eInterpretation examples for *CYP2D6* duplications are provided. Interpretations will need to be modified for instances when *CYP2D6* multiplications are present.

SUPPLEMENTAL TABLE S15. EXAMPLE IMPLEMENTATION OF THIS GUIDELINE FOR CYP2C19: PHARMACOGENETIC DIPLOTYPE/PHENOTYPE SUMMARY ENTRIES^A

Diplotype Test Result for <i>CYP2C19</i>	Coded Genotype/Phenotype Summary ^b	EHR Priority Result Notation ^b	Consultation (Interpretation) Text Provided with Test Result ^d
*17/*17	CYP2C19 Ultrarapid Metabolizer	Abnormal/Priority/High Risk	This result signifies that the patient has two copies of an increased function allele (*17/*17). Based on the genotype result this patient is predicted to be an ultrarapid metabolizer of CYP2C19 substrates. This patient may be at risk for an adverse or poor response to medications that are metabolized by CYP2C19. To avoid an untoward drug response, dose adjustments may be necessary for medications metabolized by CYP2C19. Please consult a clinical pharmacist for more information about how CYP2C19 metabolic status influences drug selection and dosing.
*1/*17	CYP2C19 Ultrarapid Metabolizer	Abnormal/Priority/High Risk	This result signifies that the patient has one copy of a normal function allele (*1) and one copy of an increased function allele (*17). Based on the genotype result this patient is predicted to be an ultrarapid metabolizer of CYP2C19 substrates. This patient may be at risk for an adverse or poor response to medications that are metabolized by CYP2C19. To avoid an untoward drug response, dose adjustments may be necessary for medications metabolized by CYP2C19. Please consult a clinical pharmacist for more information about how CYP2C19 metabolic status influences drug selection and dosing.

Diplotype Test Result for	Coded Genotype/Phenotype	EHR Priority Result Notation ^b	Consultation (Interpretation) Text Provided with Test
<i>CYP2C19</i>	Summary ^b		Kesut
*1/*1	None	Normal/Routine/Low Risk	This result signifies that the patient has two copies of a normal function allele $(*1/*1)$. Based on the genotype result this patient is predicted to be an extensive (normal) metabolizer of CYP2C19 substrates. There is no reason to selectively adjust the dose of most medications that are metabolized by CYP2C19. Please consult a clinical pharmacist for more information about how CYP2C19 metabolic status influences drug selection and dosing.
*1/*2	CYP2C19 Intermediate Metabolizer	Abnormal/Priority/High Risk	This result signifies that the patient has one copy of a normal function allele (*1) and one copy of a no function allele (*2). Based on the genotype result this patient is predicted to be an intermediate metabolizer of CYP2C19 substrates. This patient may be at risk for an adverse or poor response to medications that are metabolized by CYP2C19. To avoid an untoward drug response, dose adjustments may be necessary for medications metabolized by CYP2C19. Please consult a clinical pharmacist for more information about how CYP2C19 metabolic status influences drug selection and dosing.
*1/*3	CYP2C19 Intermediate Metabolizer	Abnormal/Priority/High Risk	This result signifies that the patient has one copy of a normal function allele (*1) and one copy of a no function allele (*3). Based on the genotype result this patient is predicted to be an intermediate metabolizer of CYP2C19 substrates. This patient may be at risk for an adverse or poor response to medications that are metabolized by CYP2C19. To avoid an untoward drug response, dose adjustments may be necessary for medications metabolized by CYP2C19. Please consult a clinical pharmacist for more information about how CYP2C19 metabolic status influences drug selection and dosing.

Diplotype Test	Coded	EHR Priority Result Notation ^b	Consultation (Interpretation) Text Provided with Test
Result for CYP2C19	Genotype/Phenotype Summary ^b		Result ^d
*2/*17	CYP2C19 Intermediate Metabolizer	Abnormal/Priority/High Risk	This result signifies that the patient has one copy of an increased function allele (*17) and one copy of a no function allele (*2). Based on the genotype result this patient is predicted to be an intermediate metabolizer of CYP2C19 substrates. This patient may be at risk for an adverse or poor response to medications that are metabolized by CYP2C19. To avoid an untoward drug response, dose adjustments may be necessary for medications metabolized by CYP2C19. Please consult a clinical pharmacist for more information about how CYP2C19 metabolic status influences drug selection and dosing.
*2/*2	CYP2C19 Poor Metabolizer	Abnormal/Priority/High Risk	This result signifies that the patient has two copies of a no function allele (*2). Based on the genotype result this patient is predicted to be a poor metabolizer of CYP2C19 substrates. This patient may be at a high risk for an adverse or poor response to medications that are metabolized by CYP2C19. To avoid an untoward drug response, dose adjustments or alternative therapeutic agents may be necessary for medications metabolized by the CYP2C19. Please consult a clinical pharmacist for more information about how CYP2C19 metabolic status influences drug selection and dosing.
*2/*3	CYP2C19 Poor Metabolizer	Abnormal/Priority/High Risk	This result signifies that the patient has two copies of a no function allele (*2/*3). Based on the genotype result this patient is predicted to be a poor metabolizer of CYP2C19 substrates. This patient may be at a high risk for an adverse or poor response to medications that are metabolized by CYP2C19. To avoid an untoward drug response, dose adjustments or alternative therapeutic agents may be necessary for medications metabolized by the CYP2C19. Please consult a clinical pharmacist for more information about how CYP2C19 metabolic status influences drug selection and dosing.

Diplotype Test Result for <i>CYP2C19</i>	Coded Genotype/Phenotype Summary ^b	EHR Priority Result Notation ^b	Consultation (Interpretation) Text Provided with Test Result ^d
*3/*3	CYP2C19 Poor Metabolizer	Abnormal/Priority/High Risk	This result signifies that the patient has two copies of a no function allele (*3). Based on the genotype result this patient is predicted to be a poor metabolizer of CYP2C19 substrates. This patient may be at a high risk for an adverse or poor response to medications that are metabolized by CYP2C19. To avoid an untoward drug response, dose adjustments or alternative therapeutic agents may be necessary for medications metabolized by the CYP2C19. Please consult a clinical pharmacist for more information about how CYP2C19 metabolic status influences drug selection and dosing.

This table is provided to show examples of how a test result could be translated into discrete fields within an EHR, including a brief interpretation that summarizes the result. The information presented here is consistent with the guideline but may need to be adapted to a given EHR's design and capabilities. Because various EHRs or organizations may require different terms different options are provided.

^aA more comprehensive table of genotype/phenotype EHR entries for possible diplotype combinations of all variants listed in **Supplemental Table S2** is available at PharmGKB (<u>https://preview.pharmgkb.org/guideline/PA166127638</u> or <u>https://preview.pharmgkb.org/guideline/PA166127639</u>)</u>

^bThe coded diplotype/phenotype summary is used to store an interpretation of the test result. This is a design decision that may differ among sites. Assignment of all Genotype/Phenotype Summaries based on diplotype is available at (<u>https://preview.pharmgkb.org/guideline/PA166127638</u> or <u>https://preview.pharmgkb.org/guideline/PA166127639</u>) ^cFor this example, a priority result is defined as a genetic test result that results in a change in drug, drug dose, or drug monitoring. ^dThe specific wording of the interpretive text may differ among sites.

SUPPLEMENTAL TABLE S16. EXAMPLE IMPLEMENTATION OF THIS GUIDELINE: POINT OF CARE CLINICAL

DECISION SUPPORT

CDS Alert trigger condition	CDS Context, relative to genetic	CDS Alert Text ^a		
CYP2D6 and parox	etine			
No <i>CYP2D6</i> test on file and paroxetine ordered	Pre-Test	<i>CYP2D6</i> genetic status may be predictive of an adverse reaction or poor response to this medication. A <i>CYP2D6</i> genotype does not appear to have been ordered for this patient. Use of an alternative drug or dose may be recommended. Please consult a clinical pharmacist ^b for more information.		
CYP2D6 UM and paroxetine ordered	Post-Test	This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a poor response due to low plasma concentrations of paroxetine. Consider selecting an alternative SSRI not extensively metabolized by CYP2D6. Please consult a clinical pharmacist for more information.		
CYP2D6 EM or IM and paroxetine ordered	Post-Test	No CDS		
CYP2D6 PM and paroxetine ordered	Post-Test	This patient is predicted to be a CYP2D6 poor metabolizer and may be at an increased risk of an adverse reaction due to elevated paroxetine plasma concentrations. Select an alternative SSRI not extensively metabolized by CYP2D6. If paroxetine is warranted, consider a 50% decrease of the initial dose and titrate to response. Please consult a clinical pharmacist for more information.		
CDS Alert trigger	CDS Context,	CDS Alert Text ^a		
------------------------	---------------------	--	--	--
condition	relative to genetic			
	testing			
CYP2D6 and fluvoxamine				
No CYP2D6 test on	Pre-Test	<i>CYP2D6</i> genetic status may be predictive of an adverse reaction or poor response		
file and		to this medication. A <i>CYP2D6</i> genotype does not appear to have been ordered for		
fluvoxamine		this patient. Use of an alternative drug or dose may be recommended. Please		
ordered		consult a clinical pharmacist ^b for more information.		
CYP2D6 UM, EM,	Post-Test	No CDS		
or IM				
CYP2D6 PM and	Post-Test	This patient is predicted to be a CYP2D6 poor metabolizer and may be at an		
fluvoxamine		increased risk of an adverse reaction due to elevated fluvoxamine plasma		
ordered		concentrations. Consider a 25-50% reduction of recommended starting dose and		
		titrate to response or use an alternative drug not metabolized by CYP2D6. Please		
		consult a clinical pharmacist for more information.		
CYP2C19 and citalopram				
No CYP2C19 test	Pre-Test	<i>CYP2C19</i> genetic status may be predictive of an adverse reaction or poor		
on file and		response to this medication. A CYP2C19 genotype does not appear to have been		
citalopram ordered		ordered for this patient. Use of an alternative drug or dose may be recommended.		
		Please consult a clinical pharmacist for more information.		
CYP2C19 UM and	Post-Test	This patient is predicted to be a CYP2C19 ultrarapid metabolizer and may be at		
citalopram ordered		an increased risk of a poor response due to low plasma concentrations of		
		citalopram. Consider selecting an alternative SSRI not extensively metabolized		
		by CYP2C19. Please consult a clinical pharmacist for more information.		
CYP2C19 EM or	Post-Test	No CDS		
IM and citalopram				
ordered				
CYP2C19 PM and	Post-Test	This patient is predicted to be a CYP2C19 poor metabolizer and may be at an		
citalopram ordered		increased risk of an adverse reaction due to elevated citalopram plasma		
		concentrations. Consider a 50% reduction of the recommended starting dose and		
		titrate to response or select alternative drug not predominantly metabolized by		
		CYP2C19. Please consult a clinical pharmacist for more information.		

CDS Alert trigger	CDS Context	CDS Alart Taxt ^a	
condition	relative to genetic		
conuntion	tosting		
CVD2C10 and excitationnum			
No CVD2C10 test		CVD2C10 constinuities status may be predictive of an adverse reaction or near response to	
no CIF2CI9 lest	Fle-Test	this mediaction A CVD2C10 construe does not support to have been addred for this	
on the and		this medication. A CTP2CT9 genotype does not appear to have been ordered for this	
escitaiopram		patient. Use of an alternative drug of dose may be recommended. Please consult a	
ordered	N T	clinical pharmacist for more information.	
CYP2C19 UM and	Post-Test	This patient is predicted to be a CYP2C19 ultrarapid metabolizer and may be at an	
escitalopram		increased risk of a poor response due to low plasma concentrations of escitalopram.	
ordered		Consider selecting an alternative SSRI not extensively metabolized by CYP2C19.	
		Please consult a clinical pharmacist for more information.	
CYP2C19 EM or	Post-Test	No CDS	
IM and			
escitalopram			
ordered			
CYP2C19 PM and	Post-Test	This patient is predicted to be a CYP2C19 poor metabolizer and may be at an	
escitalopram		increased risk of an adverse reaction due to elevated escitalopram plasma	
ordered		concentrations. Consider a 50% reduction of the recommended starting dose and	
		titrate to response or select alternative drug not predominantly metabolized by	
		CYP2C19. Please consult a clinical pharmacist for more information.	
CYP2C19 and sertraline			
No CYP2C19 test	Pre-Test	CYP2C19 genetic status may be predictive of an adverse reaction or poor response to	
on file and		this medication. A CYP2C19 genotype does not appear to have been ordered for this	
sertraline ordered		patient. Use of an alternative drug or dose may be recommended. Please consult a	
		clinical pharmacist for more information.	
CYP2C19 UM, EM	Post-Test	No CDS	
or IM and sertraline			
ordered			
CYP2C19 PM and	Post-Test	This patient is predicted to be a CYP2C19 poor metabolizer and may be at an	
sertraline ordered		increased risk of an adverse reaction due to elevated sertraline plasma	
		concentrations. Consider a 50% reduction of the recommended starting dose and	
		titrate to response or select alternative drug not predominantly metabolized by	
		CYP2C19. Please consult a clinical pharmacist for more information.	

^aThe specific wording of the alert text may differ among sites. ^bPharmacist, pharmacologist, or a clinician with pharmacogenetic expertise/training.

REFERENCES

1. Scott SA, Sangkuhl K, Gardner EE, Stein CM, Hulot JS, Johnson JA, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. Clinical pharmacology and therapeutics. 2011;90(2):328-32.

2. Crews KR, Gaedigk A, Dunnenberger HM, Klein TE, Shen DD, Callaghan JT, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype. Clinical pharmacology and therapeutics. 2012;91(2):321-6.

3. Scott SA, Sangkuhl K, Stein CM, Hulot JS, Mega JL, Roden DM, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clinical pharmacology and therapeutics. 2013;94(3):317-23. Epub 2013/05/24.

4. Crews KR, Gaedigk A, Dunnenberger HM, Leeder JS, Klein TE, Caudle KE, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update. Clinical pharmacology and therapeutics. 2014;95(4):376-82. Epub 2014/01/25.

5. Robarge JD, Li L, Desta Z, Nguyen A, Flockhart DA. The star-allele nomenclature: retooling for translational genomics. Clinical pharmacology and therapeutics. 2007;82(3):244-8. Epub 2007/08/19.

6. Hicks JK, Crews KR, Hoffman JM, Kornegay NM, Wilkinson MR, Lorier R, et al. A clinician-driven automated system for integration of pharmacogenetic interpretations into an electronic medical record. Clinical pharmacology and therapeutics. 2012;92(5):563-6. Epub 2012/09/20.

7. Gaedigk A, Simon SD, Pearce RE, Bradford LD, Kennedy MJ, Leeder JS. The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clinical pharmacology and therapeutics. 2008;83(2):234-42. Epub 2007/11/01.

8. A LL, Dorado P, Berecz R, Gonzalez AP, Penas LEM. Effect of CYP2D6 and CYP2C9 genotypes on fluoxetine and norfluoxetine plasma concentrations during steady-state conditions. European journal of clinical pharmacology. 2004;59(12):869-73. Epub 2004/01/17.

9. Hicks JK, Swen JJ, Gaedigk A. Challenges in CYP2D6 phenotype assignment from genotype data: a critical assessment and call for standardization. Current drug metabolism. 2014;15(2):218-32. Epub 2014/02/15.

10. Dahl ML, Johansson I, Bertilsson L, Ingelman-Sundberg M, Sjoqvist F. Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. The Journal of pharmacology and experimental therapeutics. 1995;274(1):516-20. Epub 1995/07/01.

11. Ramamoorthy A, Skaar TC. Gene copy number variations: it is important to determine which allele is affected. Pharmacogenomics. 2011;12(3):299-301. Epub 2011/04/01.

12. Hicks JK, Crews KR, Hoffman JM, Kornegay NM, Wilkinson MR, Lorier R, et al. A Clinician-Driven Automated System for Integration of Pharmacogenetic Interpretations Into an Electronic Medical Record. Clinical pharmacology and therapeutics. 2012. Epub 2012/09/20.

13. Wang D, Papp AC, Sun X. Functional characterization of CYP2D6 enhancer polymorphisms. Human molecular genetics. 2014. Epub 2014/11/09.

14. Wang D, Poi MJ, Sun X, Gaedigk A, Leeder JS, Sadee W. Common CYP2D6 polymorphisms affecting alternative splicing and transcription: long-range haplotypes with two

regulatory variants modulate CYP2D6 activity. Human molecular genetics. 2014;23(1):268-78. Epub 2013/08/30.

15. de Vos A, van der Weide J, Loovers HM. Association between CYP2C19*17 and metabolism of amitriptyline, citalopram and clomipramine in Dutch hospitalized patients. The pharmacogenomics journal. 2011;11(5):359-67. Epub 2010/06/10.

16. Sibbing D, Gebhard D, Koch W, Braun S, Stegherr J, Morath T, et al. Isolated and interactive impact of common CYP2C19 genetic variants on the antiplatelet effect of chronic clopidogrel therapy. Journal of thrombosis and haemostasis : JTH. 2010;8(8):1685-93. Epub 2010/05/25.

17. Whirl-Carrillo M, McDonagh EM, Hebert JM, Gong L, Sangkuhl K, Thorn CF, et al. Pharmacogenomics knowledge for personalized medicine. Clinical pharmacology and therapeutics. 2012;92(4):414-7. Epub 2012/09/21.

18. Lyon E, Gastier Foster J, Palomaki GE, Pratt VM, Reynolds K, Sabato MF, et al. Laboratory testing of CYP2D6 alleles in relation to tamoxifen therapy. Genetics in medicine : official journal of the American College of Medical Genetics. 2012. Epub 2012/09/08.

19. Sim SC, Nordin L, Andersson TM, Virding S, Olsson M, Pedersen NL, et al. Association between CYP2C19 polymorphism and depressive symptoms. American journal of medical genetics Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics. 2010;153B(6):1160-6. Epub 2010/05/15.

20. Persson A, Sim SC, Virding S, Onishchenko N, Schulte G, Ingelman-Sundberg M. Decreased hippocampal volume and increased anxiety in a transgenic mouse model expressing the human CYP2C19 gene. Molecular psychiatry. 2014;19(6):733-41. Epub 2013/07/24.

21. Bijl MJ, Luijendijk HJ, van den Berg JF, Visser LE, van Schaik RH, Hofman A, et al. Association between the CYP2D6*4 polymorphism and depression or anxiety in the elderly. Pharmacogenomics. 2009;10(4):541-7. Epub 2009/04/21.

22. Gonzalez I, Penas-Lledo EM, Perez B, Dorado P, Alvarez M, A LL. Relation between CYP2D6 phenotype and genotype and personality in healthy volunteers. Pharmacogenomics. 2008;9(7):833-40. Epub 2008/07/04.

23. Suzuki E, Kitao Y, Ono Y, Iijima Y, Inada T. Cytochrome P450 2D6 polymorphism and character traits. Psychiatric genetics. 2003;13(2):111-3. Epub 2003/06/05.

24. Roberts RL, Luty SE, Mulder RT, Joyce PR, Kennedy MA. Association between cytochrome P450 2D6 genotype and harm avoidance. American journal of medical genetics Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics. 2004;127B(1):90-3. Epub 2004/04/27.

25. Penas-Lledo EM, Dorado P, Aguera Z, Gratacos M, Estivill X, Fernandez-Aranda F, et al. CYP2D6 polymorphism in patients with eating disorders. The pharmacogenomics journal. 2012;12(2):173-5. Epub 2010/09/30.

26. Penas-Lledo EM, Llerena A. CYP2D6 variation, behaviour and psychopathology: implications for pharmacogenomics-guided clinical trials. British journal of clinical pharmacology. 2014;77(4):673-83. Epub 2013/09/17.

27. Penas LEM, Dorado P, Pacheco R, Gonzalez I, A LL. Relation between CYP2D6 genotype, personality, neurocognition and overall psychopathology in healthy volunteers. Pharmacogenomics. 2009;10(7):1111-20. Epub 2009/07/17.

28. Llerena A, Edman G, Cobaleda J, Benitez J, Schalling D, Bertilsson L. Relationship between personality and debrisoquine hydroxylation capacity. Suggestion of an endogenous

neuroactive substrate or product of the cytochrome P4502D6. Acta psychiatrica Scandinavica. 1993;87(1):23-8. Epub 1993/01/01.

29. Penas-Lledo E, Guillaume S, Naranjo ME, Delgado A, Jaussent I, Blasco-Fontecilla H, et al. A combined high CYP2D6-CYP2C19 metabolic capacity is associated with the severity of suicide attempt as measured by objective circumstances. The pharmacogenomics journal. 2014. Epub 2014/08/13.

30. Blasco-Fontecilla H, Penas-Lledo E, Vaquero-Lorenzo C, Dorado P, Saiz-Ruiz J, Llerena A, et al. CYP2D6 Polymorphism and Mental and Personality Disorders in Suicide Attempters. Journal of personality disorders. 2013. Epub 2013/02/13.

31. Penas-Lledo EM, Blasco-Fontecilla H, Dorado P, Vaquero-Lorenzo C, Baca-Garcia E, Llerena A. CYP2D6 and the severity of suicide attempts. Pharmacogenomics. 2012;13(2):179-84. Epub 2011/12/07.

32. Penas-Lledo EM, Dorado P, Aguera Z, Gratacos M, Estivill X, Fernandez-Aranda F, et al. High risk of lifetime history of suicide attempts among CYP2D6 ultrarapid metabolizers with eating disorders. Molecular psychiatry. 2011;16(7):691-2. Epub 2011/02/16.

33. Zackrisson AL, Lindblom B, Ahlner J. High frequency of occurrence of CYP2D6 gene duplication/multiduplication indicating ultrarapid metabolism among suicide cases. Clinical pharmacology and therapeutics. 2010;88(3):354-9. Epub 2009/11/13.

34. Ripke S, Wray NR, Lewis CM, Hamilton SP, Weissman MM, Breen G, et al. A megaanalysis of genome-wide association studies for major depressive disorder. Molecular psychiatry. 2013;18(4):497-511. Epub 2012/04/05.

35. Wang H, Song K, Chen Z, Yu Y. Poor metabolizers at the cytochrome P450 2C19 loci is at increased risk of developing cancer in Asian populations. PloS one. 2013;8(8):e73126. Epub 2013/09/10.

36. Zhou LP, Luan H, Dong XH, Jin GJ, Man DL, Shang H. Genetic variants of CYP2D6 gene and cancer risk: a HuGE systematic review and meta-analysis. Asian Pacific journal of cancer prevention : APJCP. 2012;13(7):3165-72. Epub 2012/09/22.

37. Meijerman I, Sanderson LM, Smits PH, Beijnen JH, Schellens JH. Pharmacogenetic screening of the gene deletion and duplications of CYP2D6. Drug metabolism reviews. 2007;39(1):45-60. Epub 2007/03/17.

38. Kim EY, Lee SS, Jung HJ, Jung HE, Yeo CW, Shon JH, et al. Robust CYP2D6 genotype assay including copy number variation using multiplex single-base extension for Asian populations. Clinica chimica acta; international journal of clinical chemistry. 2010;411(23-24):2043-8. Epub 2010/09/11.

39. Gaedigk A. Complexities of CYP2D6 gene analysis and interpretation. International review of psychiatry. 2013;25(5):534-53. Epub 2013/10/25.

40. Scott SA, Martis S, Peter I, Kasai Y, Kornreich R, Desnick RJ. Identification of CYP2C19*4B: pharmacogenetic implications for drug metabolism including clopidogrel responsiveness. The pharmacogenomics journal. 2012;12(4):297-305. Epub 2011/03/02.

41. Skierka JM, Black JL, 3rd. Analysis of compound heterozygous CYP2C19 genotypes to determine cis and trans configurations. Pharmacogenomics. 2014;15(9):1197-205. Epub 2014/08/22.

42. Scott SA, Tan Q, Baber U, Yang Y, Martis S, Bander J, et al. An allele-specific PCR system for rapid detection and discrimination of the CYP2C19 *4A, *4B, and *17 alleles: implications for clopidogrel response testing. The Journal of molecular diagnostics : JMD. 2013;15(6):783-9. Epub 2013/09/10.

43. Sorich MJ, Polasek TM, Wiese MD. Systematic review and meta-analysis of the association between cytochrome P450 2C19 genotype and bleeding. Thrombosis and haemostasis. 2012;108(1):199-200. Epub 2012/05/04.

44. Hicks JK, Swen JJ, Thorn CF, Sangkuhl K, Kharasch ED, Ellingrod VL, et al. Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. Clinical pharmacology and therapeutics. 2013;93(5):402-8. Epub 2013/03/15.

45. Sibbing D, Koch W, Gebhard D, Schuster T, Braun S, Stegherr J, et al. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation. 2010;121(4):512-8. Epub 2010/01/20.

46. Sim SC, Risinger C, Dahl ML, Aklillu E, Christensen M, Bertilsson L, et al. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clinical pharmacology and therapeutics. 2006;79(1):103-13. Epub 2006/01/18.

47. Li-Wan-Po A, Girard T, Farndon P, Cooley C, Lithgow J. Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17. British journal of clinical pharmacology. 2010;69(3):222-30. Epub 2010/03/18.

48. Baumann P, Rochat B. Comparative pharmacokinetics of selective serotonin reuptake inhibitors: a look behind the mirror. International clinical psychopharmacology. 1995;10 Suppl 1:15-21. Epub 1995/03/01.

49. McDonagh EM, Whirl-Carrillo M, Garten Y, Altman RB, Klein TE. From pharmacogenomic knowledge acquisition to clinical applications: the PharmGKB as a clinical pharmacogenomic biomarker resource. Biomarkers in medicine. 2011;5(6):795-806. Epub 2011/11/23.

50. Fuller RW, Snoddy HD, Krushinski JH, Robertson DW. Comparison of norfluoxetine enantiomers as serotonin uptake inhibitors in vivo. Neuropharmacology. 1992;31(10):997-1000. Epub 1992/10/01.

51. Scordo MG, Spina E, Dahl ML, Gatti G, Perucca E. Influence of CYP2C9, 2C19 and 2D6 genetic polymorphisms on the steady-state plasma concentrations of the enantiomers of fluoxetine and norfluoxetine. Basic & clinical pharmacology & toxicology. 2005;97(5):296-301. Epub 2005/10/21.

52. Fjordside L, Jeppesen U, Eap CB, Powell K, Baumann P, Brosen K. The stereoselective metabolism of fluoxetine in poor and extensive metabolizers of sparteine. Pharmacogenetics. 1999;9(1):55-60. Epub 1999/04/20.

53. Wong DT, Bymaster FP, Reid LR, Mayle DA, Krushinski JH, Robertson DW. Norfluoxetine enantiomers as inhibitors of serotonin uptake in rat brain. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 1993;8(4):337-44. Epub 1993/06/01.

54. Gassó P, Rodríguez N, Mas S, Pagerols M, Blázquez A, Plana MT, et al. Effect of *CYP2D6*, *CYP2C9* and *ABCB1* genotypes on fluoxetine plasma concentration and clinical improvement in children and adolescent patients. Pharmacogenomics J. 2014:aop, 25 March 2014, PMID 244663076.

55. Findling RL, Nucci G, Piergies AA, Gomeni R, Bartolic EI, Fong R, et al. Multiple dose pharmacokinetics of paroxetine in children and adolescents with major depressive disorder or obsessive-compulsive disorder. Neuropsychopharmacology. 2006;31:1274-85.

56. Carlsson B, Olsson G, Reis M, Wålander J, Nordin C, Lundmark J, et al. Enantioselective analysis of citalopram and metabolites in adolescents. Ther Drug Monitor. 2001;23:658-64.

57. Lam YW, Gaedigk A, Ereshefsky L, Alfaro CL, Simpson J. CYP2D6 inhibition by selective serotonin reuptake inhibitors: analysis of achievable steady-state plasma concentrations and the effect of ultrarapid metabolism at CYP2D6. Pharmacotherapy. 2002;22(8):1001-6. Epub 2002/08/14.

58. Gex-Fabry M, Eap CB, Oneda B, Gervasoni N, Aubry JM, Bondolfi G, et al. CYP2D6 and ABCB1 genetic variability: influence on paroxetine plasma level and therapeutic response. Therapeutic drug monitoring. 2008;30(4):474-82. Epub 2008/07/22.

59. Guzey C, Spigset O. Low serum concentrations of paroxetine in CYP2D6 ultrarapid metabolizers. Journal of clinical psychopharmacology. 2006;26(2):211-2. Epub 2006/04/25.

60. Matchar DB, Thakur ME, Grossman I, McCrory DC, Orlando LA, Steffens DC, et al. Testing for Cytochrome P450 Polymorphisms in Adults With Non-Psychotic Depression Treated With Selective Serotonin Reuptake Inhibitors (SSRIs). Evidence Report/Technology Assessment No 146 (Prepared by the Duke Evidence-based Practice Center under Contract No 290-02-0025). January 2007; AHRQ Publication No. 07-E002. Rockville, MD: Agency for Healthcare Research and Quality.

61. Swen JJ, Nijenhuis M, de Boer A, Grandia L, Maitland-van der Zee AH, Mulder H, et al. Pharmacogenetics: from bench to byte--an update of guidelines. Clinical pharmacology and therapeutics. 2011;89(5):662-73. Epub 2011/03/18.

62. Valdes R, Payne DA, Linder MW. Laboratory analysis and application of pharmacogenetics to clinical practice. The National Academy of Clinical Biochemistry (NACB)
- Laboratory Medicine Practice Guidelines. Washington, DC2010.

63. Adolescents PoAGfAa. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. 2011. p. 1-166.

64. Shuldiner AR, Relling MV, Peterson JF, Hicks JK, Freimuth RR, Sadee W, et al. The Pharmacogenomics Research Network Translational Pharmacogenetics Program: overcoming challenges of real-world implementation. Clinical pharmacology and therapeutics. 2013;94(2):207-10. Epub 2013/04/17.

65. Wilke RA, Xu H, Denny JC, Roden DM, Krauss RM, McCarty CA, et al. The emerging role of electronic medical records in pharmacogenomics. Clinical pharmacology and therapeutics. 2011;89(3):379-86. Epub 2011/01/21.

66. Peterson JF, Bowton E, Field JR, Beller M, Mitchell J, Schildcrout J, et al. Electronic health record design and implementation for pharmacogenomics: a local perspective. Genetics in medicine : official journal of the American College of Medical Genetics. 2013;15(10):833-41. Epub 2013/09/07.

67. Gottesman O, Kuivaniemi H, Tromp G, Faucett WA, Li R, Manolio TA, et al. The Electronic Medical Records and Genomics (eMERGE) Network: past, present, and future. Genetics in medicine : official journal of the American College of Medical Genetics. 2013;15(10):761-71. Epub 2013/06/08.

68. Kullo IJ, Jarvik GP, Manolio TA, Williams MS, Roden DM. Leveraging the electronic health record to implement genomic medicine. Genetics in medicine : official journal of the American College of Medical Genetics. 2013;15(4):270-1. Epub 2012/09/29.

69. Martin MA, Hoffman JM, Freimuth RR, Klein TE, Dong BJ, Pirmohamed M, et al. Clinical pharmacogenetics implementation consortium guidelines for hla-B genotype and

abacavir dosing: 2014 update. Clinical pharmacology and therapeutics. 2014;95(5):499-500. Epub 2014/02/25.

70. Bell GC, Crews KR, Wilkinson MR, Haidar CE, Hicks JK, Baker DK, et al. Development and use of active clinical decision support for preemptive pharmacogenomics. Journal of the American Medical Informatics Association : JAMIA. 2013. Epub 2013/08/28.

71. Pulley JM, Denny JC, Peterson JF, Bernard GR, Vnencak-Jones CL, Ramirez AH, et al. Operational implementation of prospective genotyping for personalized medicine: the design of the Vanderbilt PREDICT project. Clinical pharmacology and therapeutics. 2012;92(1):87-95. Epub 2012/05/17.

72. Gaedigk A, Frank D, Fuhr U. Identification of a novel non-functional CYP2D6 allele, CYP2D6*69, in a Caucasian poor metabolizer individual. European journal of clinical pharmacology. 2009;65(1):97-100. Epub 2008/09/18.

73. Gaedigk A, Ndjountche L, Divakaran K, Dianne Bradford L, Zineh I, Oberlander TF, et al. Cytochrome P4502D6 (CYP2D6) gene locus heterogeneity: characterization of gene duplication events. Clinical pharmacology and therapeutics. 2007;81(2):242-51. Epub 2007/01/30.

74. Muroi Y, Saito T, Takahashi M, Sakuyama K, Niinuma Y, Ito M, et al. Functional Characterization of Wild-type and 49 CYP2D6 Allelic Variants for N-Desmethyltamoxifen 4-Hydroxylation Activity. Drug metabolism and pharmacokinetics. 2014;29(5):360-6. Epub 2014/03/22.

75. Rosenberg NA, Mahajan S, Ramachandran S, Zhao C, Pritchard JK, Feldman MW. Clines, clusters, and the effect of study design on the inference of human population structure. PLoS genetics. 2005;1(6):e70. Epub 2005/12/16.

76. Rosenberg NA, Pritchard JK, Weber JL, Cann HM, Kidd KK, Zhivotovsky LA, et al. Genetic structure of human populations. Science. 2002;298(5602):2381-5. Epub 2002/12/21.

77. Gaedigk A, Ndjountche L, Leeder JS, Bradford LD. Limited association of the 2988g > a single nucleotide polymorphism with CYP2D641 in black subjects. Clinical pharmacology and therapeutics. 2005;77(3):228-30; author reply 30-1. Epub 2005/03/01.

78. Suzuki Y, Sawamura K, Someya T. Polymorphisms in the 5-hydroxytryptamine 2A receptor and CytochromeP4502D6 genes synergistically predict fluvoxamine-induced side effects in japanese depressed patients. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2006;31(4):825-31. Epub 2005/10/06.

79. Suzuki Y, Sugai T, Fukui N, Watanabe J, Ono S, Inoue Y, et al. CYP2D6 genotype and smoking influence fluvoxamine steady-state concentration in Japanese psychiatric patients: lessons for genotype-phenotype association study design in translational pharmacogenetics. J Psychopharmacol. 2011;25(7):908-14. Epub 2010/06/16.

80. Carrillo JA, Dahl ML, Svensson JO, Alm C, Rodriguez I, Bertilsson L. Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2 activity. Clinical pharmacology and therapeutics. 1996;60(2):183-90. Epub 1996/08/01.

81. Spigset O, Granberg K, Hagg S, Norstrom A, Dahlqvist R. Relationship between fluvoxamine pharmacokinetics and CYP2D6/CYP2C19 phenotype polymorphisms. European journal of clinical pharmacology. 1997;52(2):129-33. Epub 1997/01/01.

82. Spigset O, Axelsson S, Norstrom A, Hagg S, Dahlqvist R. The major fluvoxamine metabolite in urine is formed by CYP2D6. European journal of clinical pharmacology. 2001;57(9):653-8. Epub 2002/01/17.

83. Watanabe J, Suzuki Y, Fukui N, Sugai T, Ono S, Inoue Y, et al. Dose-dependent effect of the CYP2D6 genotype on the steady-state fluvoxamine concentration. Therapeutic drug monitoring. 2008;30(6):705-8. Epub 2008/11/04.

84. Charlier C, Broly F, Lhermitte M, Pinto E, Ansseau M, Plomteux G. Polymorphisms in the CYP 2D6 gene: association with plasma concentrations of fluoxetine and paroxetine. Therapeutic drug monitoring. 2003;25(6):738-42. Epub 2003/11/26.

85. Sindrup SH, Brosen K, Gram LF, Hallas J, Skjelbo E, Allen A, et al. The relationship between paroxetine and the sparteine oxidation polymorphism. Clinical pharmacology and therapeutics. 1992;51(3):278-87. Epub 1992/03/01.

86. Zourkova A, Hadasova E. Paroxetine-induced conversion of cytochrome P450 2D6 phenotype and occurence of adverse effects. General physiology and biophysics. 2003;22(1):103-13. Epub 2003/07/23.

87. Solai LK, Pollock BG, Mulsant BH, Frye RF, Miller MD, Sweet RA, et al. Effect of nortriptyline and paroxetine on CYP2D6 activity in depressed elderly patients. Journal of clinical psychopharmacology. 2002;22(5):481-6. Epub 2002/09/28.

88. Findling RL, Reed MD, Blumer JL. Pharmacological treatment of depression in children and adolescents. Paediatric drugs. 1999;1(3):161-82. Epub 2000/08/11.

89. Feng Y, Pollock BG, Ferrell RE, Kimak MA, Reynolds CF, 3rd, Bies RR. Paroxetine: population pharmacokinetic analysis in late-life depression using sparse concentration sampling. British journal of clinical pharmacology. 2006;61(5):558-69. Epub 2006/05/04.

90. Findling RL, Nucci G, Piergies AA, Gomeni R, Bartolic EI, Fong R, et al. Multiple dose pharmacokinetics of paroxetine in children and adolescents with major depressive disorder or obsessive-compulsive disorder. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2006;31(6):1274-85. Epub 2005/12/02.

91. Sawamura K, Suzuki Y, Someya T. Effects of dosage and CYP2D6-mutated allele on plasma concentration of paroxetine. European journal of clinical pharmacology. 2004;60(8):553-7. Epub 2004/09/07.

92. Van Nieuwerburgh FC, Denys DA, Westenberg HG, Deforce DL. Response to serotonin reuptake inhibitors in OCD is not influenced by common CYP2D6 polymorphisms. International journal of psychiatry in clinical practice. 2009;13(1):345-8. Epub 2010/02/23.

93. Saruwatari J, Nakashima H, Tsuchimine S, Nishimura M, Ogusu N, Yasui-Furukori N. Possible impact of the CYP2D6*10 polymorphism on the nonlinear pharmacokinetic parameter estimates of paroxetine in Japanese patients with major depressive disorders. Pharmacogenomics and personalized medicine. 2014;7:121-7. Epub 2014/05/29.

94. Zourkova A, Ceskova E, Hadasova E, Ravcukova B. Links among paroxetine-induced sexual dysfunctions, gender, and CYP2D6 activity. Journal of sex & marital therapy. 2007;33(4):343-55. Epub 2007/06/02.

95. Sato A, Okura Y, Minagawa S, Ohno Y, Fujita S, Kondo D, et al. Life-threatening serotonin syndrome in a patient with chronic heart failure and CYP2D6*1/*5. Mayo Clinic proceedings. 2004;79(11):1444-8. Epub 2004/11/17.

96. Murphy GM, Jr., Kremer C, Rodrigues HE, Schatzberg AF. Pharmacogenetics of antidepressant medication intolerance. The American journal of psychiatry. 2003;160(10):1830-5. Epub 2003/09/30.

97. Stedman CA, Begg EJ, Kennedy MA, Roberts R, Wilkinson TJ. Cytochrome P450 2D6 genotype does not predict SSRI (fluoxetine or paroxetine) induced hyponatraemia. Human psychopharmacology. 2002;17(4):187-90. Epub 2002/10/31.

98. Sugai T, Suzuki Y, Sawamura K, Fukui N, Inoue Y, Someya T. The effect of 5hydroxytryptamine 3A and 3B receptor genes on nausea induced by paroxetine. The pharmacogenomics journal. 2006;6(5):351-6. Epub 2006/03/15.

99. Grasmader K, Verwohlt PL, Rietschel M, Dragicevic A, Muller M, Hiemke C, et al. Impact of polymorphisms of cytochrome-P450 isoenzymes 2C9, 2C19 and 2D6 on plasma concentrations and clinical effects of antidepressants in a naturalistic clinical setting. European journal of clinical pharmacology. 2004;60(5):329-36. Epub 2004/05/29.

100. Huezo-Diaz P, Perroud N, Spencer EP, Smith R, Sim S, Virding S, et al. CYP2C19 genotype predicts steady state escitalopram concentration in GENDEP. J Psychopharmacol. 2012;26(3):398-407. Epub 2011/09/20.

101. Rudberg I, Mohebi B, Hermann M, Refsum H, Molden E. Impact of the ultrarapid CYP2C19*17 allele on serum concentration of escitalopram in psychiatric patients. Clinical pharmacology and therapeutics. 2008;83(2):322-7. Epub 2007/07/13.

102. Tsai MH, Lin KM, Hsiao MC, Shen WW, Lu ML, Tang HS, et al. Genetic polymorphisms of cytochrome P450 enzymes influence metabolism of the antidepressant escitalopram and treatment response. Pharmacogenomics. 2010;11(4):537-46. Epub 2010/03/31.
103. Herrlin K, Yasui-Furukori N, Tybring G, Widen J, Gustafsson LL, Bertilsson L.

Metabolism of citalopram enantiomers in CYP2C19/CYP2D6 phenotyped panels of healthy Swedes. British journal of clinical pharmacology. 2003;56(4):415-21. Epub 2003/09/13.

104. Noehr-Jensen L, Zwisler ST, Larsen F, Sindrup SH, Damkier P, Nielsen F, et al. Impact of CYP2C19 phenotypes on escitalopram metabolism and an evaluation of pupillometry as a serotonergic biomarker. European journal of clinical pharmacology. 2009;65(9):887-94. Epub 2009/05/01.

105. Yin OQ, Wing YK, Cheung Y, Wang ZJ, Lam SL, Chiu HF, et al. Phenotype-genotype relationship and clinical effects of citalopram in Chinese patients. Journal of clinical psychopharmacology. 2006;26(4):367-72. Epub 2006/07/21.

106. Fudio S, Borobia AM, Pinana E, Ramirez E, Tabares B, Guerra P, et al. Evaluation of the influence of sex and CYP2C19 and CYP2D6 polymorphisms in the disposition of citalopram. European journal of pharmacology. 2010;626(2-3):200-4. Epub 2009/10/21.

107. Yu BN, Chen GL, He N, Ouyang DS, Chen XP, Liu ZQ, et al. Pharmacokinetics of citalopram in relation to genetic polymorphism of CYP2C19. Drug metabolism and disposition: the biological fate of chemicals. 2003;31(10):1255-9. Epub 2003/09/17.

108. Chen B, Xu Y, Jiang T, Feng R, Sun J, Zhang W, et al. Estimation of CYP2D6*10 genotypes on citalopram disposition in Chinese subjects by population pharmacokinetic assay. Journal of clinical pharmacy and therapeutics. 2013;38(6):504-11. Epub 2013/08/29.

109. Hodgson K, Tansey K, Dernovsek MZ, Hauser J, Henigsberg N, Maier W, et al. Genetic differences in cytochrome P450 enzymes and antidepressant treatment response. J Psychopharmacol. 2014;28(2):133-41. Epub 2013/11/22.

110. Ohlsson Rosenborg S, Mwinyi J, Andersson M, Baldwin RM, Pedersen RS, Sim SC, et al. Kinetics of omeprazole and escitalopram in relation to the CYP2C19*17 allele in healthy subjects. European journal of clinical pharmacology. 2008;64(12):1175-9. Epub 2008/07/26.

111. Kumar Y, Kung S, Shinozaki G. CYP2C19 variation, not citalopram dose nor serum level, is associated with QTc prolongation. J Psychopharmacol. 2014;28(12):1143-8. Epub 2014/08/15.

112. Mrazek DA, Biernacka JM, O'Kane DJ, Black JL, Cunningham JM, Drews MS, et al. CYP2C19 variation and citalopram response. Pharmacogenetics and genomics. 2011;21(1):1-9. Epub 2010/12/31.

113. Hodgson K, Uher R, Crawford AA, Lewis G, O'Donovan MC, Keers R, et al. Genetic predictors of antidepressant side effects: a grouped candidate gene approach in the Genome-Based Therapeutic Drugs for Depression (GENDEP) study. J Psychopharmacol. 2014;28(2):142-50. Epub 2014/01/15.

114. Peters EJ, Slager SL, Kraft JB, Jenkins GD, Reinalda MS, McGrath PJ, et al. Pharmacokinetic genes do not influence response or tolerance to citalopram in the STAR*D sample. PloS one. 2008;3(4):e1872. Epub 2008/04/03.

115. Han KM, Chang HS, Choi IK, Ham BJ, Lee MS. CYP2D6 P34S Polymorphism and Outcomes of Escitalopram Treatment in Koreans with Major Depression. Psychiatry investigation. 2013;10(3):286-93. Epub 2013/12/05.

116. Chang M, Tybring G, Dahl ML, Lindh JD. Impact of cytochrome P450 2C19 polymorphisms on citalopram/escitalopram exposure: a systematic review and meta-analysis. Clinical pharmacokinetics. 2014;53(9):801-11. Epub 2014/08/27.

117. Eap CB, Bondolfi G, Zullino D, Savary-Cosendai L, Powell-Golay K, Kosel M, et al. Concentrations of the enantiomers of fluoxetine and norfluoxetine after multiple doses of fluoxetine in cytochrome P4502D6 poor and extensive metabolizers. Journal of clinical psychopharmacology. 2001;21(3):330-4. Epub 2001/06/02.

118. Hamelin BA, Turgeon J, Vallee F, Belanger PM, Paquet F, LeBel M. The disposition of fluoxetine but not sertraline is altered in poor metabolizers of debrisoquin. Clinical pharmacology and therapeutics. 1996;60(5):512-21. Epub 1996/11/01.

119. Gasso P, Rodriguez N, Mas S, Pagerols M, Blazquez A, Plana MT, et al. Effect of CYP2D6, CYP2C9 and ABCB1 genotypes on fluoxetine plasma concentrations and clinical improvement in children and adolescent patients. The pharmacogenomics journal. 2014;14(5):457-62. Epub 2014/03/26.

120. Sallee FR, DeVane CL, Ferrell RE. Fluoxetine-related death in a child with cytochrome P-450 2D6 genetic deficiency. Journal of child and adolescent psychopharmacology. 2000;10(1):27-34. Epub 2000/04/08.

121. Roberts RL, Mulder RT, Joyce PR, Luty SE, Kennedy MA. No evidence of increased adverse drug reactions in cytochrome P450 CYP2D6 poor metabolizers treated with fluoxetine or nortriptyline. Human psychopharmacology. 2004;19(1):17-23. Epub 2004/01/13.

122. Rudberg I, Hermann M, Refsum H, Molden E. Serum concentrations of sertraline and Ndesmethyl sertraline in relation to CYP2C19 genotype in psychiatric patients. European journal of clinical pharmacology. 2008;64(12):1181-8. Epub 2008/08/05.

123. Wang JH, Liu ZQ, Wang W, Chen XP, Shu Y, He N, et al. Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19. Clinical pharmacology and therapeutics. 2001;70(1):42-7. Epub 2001/07/14.